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1. ABSTRACT 
 
Melanoma patients carry a high risk of developing brain metastases and 
improvements in survival are still measured in weeks or months. The aim of this 
thesis was to study the biology of melanoma brain metastasis and find new 
therapeutic approaches. In Paper I, we reviewed the current literature on animal 
models of brain metastasis. Many models are available and have provided valuable 
insights, but technical and biologic limitations have hampered clinical translation. In 
Paper II, we reported on the development and validation of a new experimental brain 
metastasis model. This model featured MRI-based automated quantification of 
nanoparticle-labeled melanoma cells in the mouse brain after intracardiac injection. 
We proposed that this model could help to increase the reproducibility and 
predictivity of mechanistic and therapeutic studies of melanoma brain metastasis. In 
Paper III, we examined the temporal, spatial and functional significance of lactate 
dehydrogenase A (LDHA) in melanoma brain metastasis. We found that LDHA 
expression was hypoxia-dependent, but did not affect tumor progression or survival in 
vivo or in a large patient cohort. In Paper IV, we applied genomics-based drug 
repositioning and carried out a comprehensive in vitro and in vivo screening of 
potential anti-melanoma brain metastasis compounds. We found the cholesterol 
analogue β-sitosterol to inhibit the growth of brain metastases and improve survival in 
established and preventive scenarios across several in vivo models. β-sitosterol 
provided broad-spectrum suppression of the important mitogen-activated protein 
kinase (MAPK) pathway and reduced mitochondrial respiration through Complex I 
inhibition. Notably, increased mitochondrial respiration is a key mediator of intrinsic 
and acquired resistance to established MAPK-targeted therapies. Together, Papers I 
and II showed that the study of melanoma biology and brain metastasis requires 
reproducible and predictive animal models. By applying such models in Papers III 
and IV, we revealed novel insights into the biology and therapy of melanoma brain 
metastasis, and suggested that mitochondrial respiration might play an imperative role 
in tumor progression and treatment resistance. 
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4. INTRODUCTION 
 
4.1. METASTASIS 
 
Metastasis is the most ominous hallmark of cancer being responsible for >90% of 
cancer mortality1. This multistep process whereby tumors spread from their primary 
site to form secondary tumors at distant sites is also the most enigmatic2. This cascade 
of events requires successful cancer cell invasion, intravasation into blood and 
lymphatic vessels, survival during transit through these vessels, arrest and 
extravasation into distant organs, and multiplication from micrometastatic to 
macrometastatic lesions within the organ parenchyma (Fig. 1). 
 
 
Figure 1 The metastatic process. Each step in this cascade is driven by the acquisition of 
genetic and/or epigenetic alterations and requires intricate cooperation between cancer cells 
and stromal cells. Hematogenous dissemination is the primary route to distant organs. 
Circulating tumor cells (CTCs) denote cancer cells with stem-like properties (e.g. enhanced 
tumorigenicity, self-renewal potential). From Chaffer et al.2. Reprinted with permission from 
the American Association for the Advancement of Science (AAAS). 
 
Primary tumors can often be cured by surgical resection and adjuvant chemo- and 
radiotherapy, whereas metastatic disease is often incurable due to its extent and 
resistance to available therapies1. Thus, future improvements in cancer treatment and 
patient prognosis are largely reliant on continued innovation seeking to prevent or 
reverse cancer metastasis. 
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4.2. BRAIN METASTASIS 
 
4.2.1. Epidemiology 
The exact prevalence and incidence of brain metastases based on population studies 
are unavailable3. Despite the incompleteness of data and inadequate ascertainment of 
cases, most studies indicate that the number of patients with brain metastases has been 
increasing and will continue to increase in coming years4,5,a. 
 
4.2.1.1. Prevalence 
Symptomatic brain metastases develop in 8.5-9.6% of all adults with cancer6,7. The 
true prevalence is probably much higher, as asymptomatic patients are not diagnosed, 
symptomatic brain metastases are not reported in patients with widespread disease, 
and patients with brain metastases are misdiagnosed as having cerebrovascular 
disease or other neurological conditions3,8. Historical autopsy series have generally 
reported higher frequencies of brain metastases than that reported in population-based 
studies. In an autopsy study of breast cancer patients, only 31% of the cases were 
diagnosed or suspected before death9. Large autopsy series have revealed brain 
metastases in 15-41% of cancer patients10,11. However, the current prevalence is 
difficult to establish due to low autopsy rates (<5%)8.  
 
4.2.1.2. Incidence 
The estimated incidence of brain metastases in the United States (US) is 7-14 persons 
per 100,000 per year (22,000-44,000 persons per year)12. A population-based study 
from the period 1935 through 1968 from Rochester in the US reported an incidence 
rate of 11.1 per 100,000 per year10. A national survey study from the US reported an 
incidence rate of 8.3 per 100,000 between 1973 and 197413. A population-based study 
from Scotland conducted in 1989-1990 reported an incidence rate of 14.3 per 
100,000; only 11% of cases had pathological confirmation and brain metastases 
accounted for 48% of all intracranial tumors14. This study also showed an exponential 
increase in incidence rates until age 74 and thereafter a decline. The age-adjusted 
incidence of hospitalization due to brain metastases doubled from 7 to 14 persons per 
100,000 per year in Sweden between 1987 and 200615. In a large retrospective cohort 

ahttp://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index 
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study from the US, the annual number of surgical resections for brain metastases 
increased by 79% from 3,900 in 1988 to 7,000 in 200016. 
 
Several factors contribute to the observed increase in incidence of brain metastases17. 
The first is the introduction and rapidly increasing availability of neuroimaging, in 
particular of magnetic resonance imaging (MRI); 20 years ago, only 2% of cancer 
patients underwent MRI as compared to 64% of patients today18. Many cancer 
patients undergo surveillance brain imaging in the absence of symptoms, and many 
clinical trials mandate MRI screening to exclude patients with brain metastases3. 
Second, there has been a steady increase in the incidence of cancers with a 
predilection for brain metastasis, such as melanomaa. Third, cancer patients live 
longer due to earlier detection and better treatment, and the population at risk of 
developing brain metastases therefore increases; this is especially important for lung 
and breast cancer, which display decreasing overall incidences17,b. For instance, 
patients diagnosed with breast cancer in Sweden in the period 2004-2006 were at a 
44% increased risk of being admitted with brain metastases as compared to patients 
diagnosed in the period 1998-200019. Fourth, many targeted therapies have limited 
bioavailability in the brain; observations suggest an increasing incidence of brain 
metastases in human epidermal growth factor receptor 2 (HER2)-positive breast 
cancer patients treated with trastuzumab, a substance that has limited ability to pass 
the blood-brain barrier (BBB)20,21 and hence creates a “sanctuary site” for tumors to 
develop within the central nervous system (CNS)8. 
 
4.2.1.3. Number and location 
Historical autopsy series have revealed a single brain metastasis in 47% of cancer 
patients11. In a surgical series of 309 patients with brain metastases, 72.1% of patients 
had one metastasis, and most of these patients had a controlled primary tumor and no 
other metastases22. Surgical series are of course biased towards limited disease both 
intra- and extracranially, as well as a good performance status and a lower age 
distribution. Clinical series of cancer patients undergoing treatment for brain 

ahttp://seer.cancer.gov/statfacts/html/melan.html 
bhttp://seer.cancer.gov/statfacts
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metastases are less biased, and have shown multiple brain metastases in 47% of 
cases23 and more than three metastases in 41% of cases24. 
 
Multiple brain metastases are more frequently seen in patients with lung cancer and 
melanoma, whereas breast, renal and colorectal cancers are more frequently 
associated with a single brain metastasis23,25. 
 
The distribution of brain metastases is generally in accordance with blood flow and 
tissue volume: cerebrum 80%, cerebellum 15% and brain stem 5%25. However, 
studies suggest that lung and breast cancer are more prone to cause cerebellar 
metastases than renal cancer, gynecological cancers and, particularly, melanoma26-28. 
 
Most patients (60-80%) with brain metastases have concurrent systemic metastases, 
of which pulmonary metastases are most frequent25,29,30. 
 
4.2.1.4. Causative primary cancers 
Any kind of cancer can disseminate to the brain30. Lung cancer, breast cancer and 
melanoma account for 67-80% of all brain metastases14,22-24,27,30,31. The most common 
reported cause of brain metastases has been lung cancer (39-56%; of which 6-15% is 
small cell lung cancer (SCLC) and 24-44% is non-small cell lung cancer (NSCLC)), 
followed by breast cancer (13-44%), melanoma (6-11%), colorectal cancer (3-9%) 
and renal cancer (2-6%); however patterns are evolving and there are also substantial 
geographical variations3,6,18,32. In a population-based study from the Detroit area in 
the US of patients diagnosed with cancer in the period 1973 to 2001, it was estimated 
that 19.9% of lung cancer patients developed brain metastases followed by melanoma 
(6.9%), renal cancer (6.5%), breast cancer (5.1%) and colorectal cancer (1.8%)6. In a 
study from Norway on patients with brain metastases, comparing the periods 1983-
1989 and 2005-2009, Nieder et al. described a reduction in lung cancer (52% versus 
40%), increase in melanoma (5% versus 9%), increases in colorectal and kidney 
cancers (8% versus 24%), and a stable incidence of breast cancer (17%)18. 
 
Usually, brain metastases develop in patients with a known history of cancer or brain 
metastases precede a diagnosis of cancer somewhere in the body. However, 
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sometimes (2-14%) the cancer of origin is not found, even at autopsy14,23,29-31,33-35. In 
a German study looking at 5,074 patients with brain metastases who were diagnosed 
and treated in 2008, 7.5% of patients had unknown primaries29. 
 
For patients with a known history of cancer, one should not presume that a single 
brain lesion is synonymous with a brain metastasis. In a randomized clinical trial 
assessing the efficacy of surgical resection for a single brain metastasis, 11% of 
patients were diagnosed with a primary CNS tumor (glioblastoma multiforme (GBM) 
and low-grade astrocytoma), abscess or inflammatory process36. 
 
4.2.2. Diagnosis 
Early detection of brain metastases is important to maximize the efficacy of available 
therapies and to minimize the morbidity of these treatments17. Brain metastases are 
established indicators of poor prognosis and there are no effective preventive 
measures; vigilant clinical monitoring is thus required for early diagnosis and 
minimization of neurological injury17. MRI is the most important modality and brain 
metastases are typically detected using contrast-enhanced T1-weighted (T1w) 
sequences. The definite diagnosis is made by standard histopathological and 
molecular analyses of surgical tissue specimens (resection or biopsy). Several 
imaging techniques, which at present are being developed preclinically, aim at early 
detection of brain metastases (see section 4.4.2.2.). 
 
The appearance of a single brain metastasis can be very similar to e.g. a GBM with 
peripheral contrast enhancement and central necrosis. Two advances in MRI 
technology can be helpful to differentiate between primary and metastatic tumors: 
magnetic resonance spectroscopy (MRS) and perfusion-weighted imaging (PWI). The 
choline to N-acetylaspartate (NAA) ratio from MRS spectra and the PWI-derived 
relative cerebral blood volume (rCBV) are similar within high-grade gliomas and 
brain metastases, but different in the peritumoral zones. Both the choline to NAA 
ratio and rCBV measurements are higher around high-grade gliomas due to their 
infiltrative growth, whereas brain metastases have close to normal choline to NAA 
ratios and rCBV measurements due to their circumscribed, non-infiltrative 
growth37,38. 
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Diffusion-weighted imaging (DWI) can indicate if a lesion is a brain metastasis or a 
brain abscess. Abscesses typically have low apparent diffusion coefficient (ADC) 
ratios and display high signal intensity (restricted diffusion) on DWI, whereas cystic 
brain metastases have high ADC ratios and low signal intensity on DWI39. MRS is 
less specific and more time-consuming, but can also show different spectra between 
abscesses and brain metastases with abscesses displaying elevated levels of acetate, 
succinate, lactate and amino acids such as valine, leucine and isoleucine40. These 
amino acids are not seen in the spectra of brain metastases. 
 
4.2.3. Treatment 
Treatment of brain metastases is multidisciplinary and based on a selective use of 
radiation and surgery17. Surgery or stereotactic radiosurgery (SRS) are the preferred 
options for patients with a newly diagnosed solitary brain metastasis and a good 
prognosis. A surgical approach is favored by mass effect (particularly relevant for 
metastases in the posterior fossa), superficial and/or accessible location, maximal 
diameter >3-4 cm and diagnostic uncertainty. SRS is favored for patients with poor 
performance status and prognosis, deep and/or inaccessible location, maximal 
diameter <2-3 cm and close proximity to eloquent brain structures. Patients with 2-4 
brain metastases are typically treated with SRS and/or whole brain radiotherapy 
(WBRT). Patients who progress after local therapy should be considered for systemic 
therapy and/or WBRT. Molecularly targeted therapies and immunotherapies offer 
great promise for defined subsets of patients. 
 
Figure 2 shows a suggested evidence-based treatment algorithm as put forward by 
Meier in 201441. A number of other factors influence decision-making, including 
physician and patient preferences (quality of life versus overall survival (OS)). 
Standardized diagnostic and treatment guidelines for brain metastases (1-3, >3 and 
leptomeningeal) are available through the National Comprehensive Cancer Network 
(NCCN)a. 
 
 

ahttp://www.nccn.org/professionals/physician_gls/pdf/cns.pdf 
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Figure 2 Treatment algorithm of single and multiple brain metastases. At all stages, consider 
clinical trial participation and systemic therapy. Surgery should be followed by radiotherapy, 
whereas adding WBRT to SRS is optional (including for patients with 2-4 brain metastases). 
WBRT, whole brain radiotherapy; SRS, stereotactic radiosurgery; RT, localized fractionated 
radiotherapy; met, metastasis. Adapted with permission from Meier R. 201441. 
 
Brain metastases management is hampered by the lack of effective chemotherapy 
beyond the BBB and inevitable concerns of radiation and surgery on surrounding 
brain structures5,42,43. Furthermore, patients with brain metastases are often excluded 
from clinical trials, leaving us uncertain about the effects of new therapeutic 
modalities44-46. New and innovative research approaches and treatment strategies are 
needed to improve the outcome of brain metastasis patients5,17,47. 
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4.2.3.1. Surgery 
For many years, surgery was performed on patients who were thought to have a single 
brain metastasis and an otherwise good prognosis48,49. However, the role of surgery 
was uncertain until Patchell et al. in 1990 showed in a prospective, randomized 
controlled trial (RCT) that surgery + postoperative radiotherapy was superior to 
radiotherapy alone for patients with a single brain metastasis; patients receiving the 
combined treatment lived longer (median 40 weeks versus 15 weeks), had fewer local 
recurrences (20% versus 50%) and remained functionally independent longer (38 
weeks versus 8 weeks)36. Previous uncontrolled and retrospective studies had reported 
conflicting results; some had found a clear benefit from surgery48,50-56 whereas others 
had not found a benefit57-60. In a 1993 RCT, Vecht et al. verified these findings 
showing a significant survival benefit (+ four months) of adding surgery to 
radiotherapy in the treatment of a single brain metastasis61. Noordijk et al. reported 
similar results in 1994 on 63 patients with a single brain metastasis; median survival 
increased from six to 10 months with the addition of surgical resection62. 
Furthermore, Patchell et al. published a randomized trial in 1998 showing that 
surgical resection and postoperative radiotherapy was superior to surgical resection 
alone with a reduced local recurrence rate (10% versus 49%), fewer distant relapses 
(14% versus 37%) and patients were less likely to die from neurologic causes (14% 
versus 44%)63. 
 
Building on these pioneering studies and others, the first evidence-based clinical 
practice guideline for the treatment of patients with brain metastases was published in 
201064. This guideline provides Level I evidence that supports the use of surgical 
resection + postoperative WBRT as compared to WBRT alone in functionally 
independent patients who spend less than 50% of time in bed and who have limited 
extracranial disease. There was insufficient evidence to conclude on management of 
patients with poor performance status, advanced systemic disease or multiple brain 
metastases. 
 
There is no established surgical recommendation based on Level I evidence for 
patients with multiple or recurrent brain metastases. However, studies suggest that in 
selected patients, surgical resection of all lesions increases survival and confers a 
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similar prognosis to that of patients operated for a single metastasis65, and repeat 
surgical resection of recurrent tumors improves survival and quality of life66,67. 
 
Evidence-based treatment recommendations are important in surgical decision-
making. However, the surgeon must balance the benefits and harms of surgery in each 
individual patient (primum non nocere). This has been clearly underscored in studies 
of GBM surgery showing three to four months survival reduction from surgically 
acquired deficits (language or motor)68, and patients with perioperative complications 
and new neurological deficits are frequently denied adjuvant chemo- and 
radiotherapy69. Important considerations in brain metastasis surgery are accessibility, 
size, number, proximity to eloquent brain structures, degree of mass effect, concurrent 
hydrocephalus and the need for a definitive diagnosis. Likewise important are age, 
comorbidity, degree of extracranial disease and performance status of the patient. 
There is no definite threshold to initiate or withhold surgery, but the patient must have 
a possibility of a reasonably functional outcome. Patients with advanced disease and 
exhausted treatment options should generally not be subjected to surgical treatment. 
 
Our ability to provide maximally safe and effective surgery for brain metastases has 
been furthered by significant advances in neuroimaging and surgical technology70-72. 
Intraoperative neuronavigation with three-dimensional (3D) volumetric rendering of 
tumors and functional structures enables the neurosurgeon to visualize the anatomy 
and track the location of surgical instruments during surgery thereby providing better 
precision of craniotomies and tumor resection (Fig. 3). Systems for image guidance, 
like Brainlab® (Brainlab AG) or StealthStation® (Medtronic Inc.), most frequently 
rely on preoperative MRI and computed tomography (CT) imaging. However, 
intraoperative imaging updates are also possible through integrated MRI solutions 
within the operating room as well as real-time ultrasound (US) imaging; these 
complementary resources can provide valuable feedback on the extent of resection 
and brain shift during surgery. The standard neurosurgical approach to a brain 
metastasis is typically microsurgical stripping of the tumor from the surrounding brain 
parenchyma using conventional white-light microscopy, assisted by preoperative 
MRI-based neuronavigation and US for deep-seated lesions73. Other techniques that 
can help to optimize the safety and efficacy of surgery include, but are not limited to, 
awake craniotomy with cortical mapping74, neurophysiological monitoring, and 
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photodynamic detection of systemically administered fluorophores like 5-
aminolevulinic acid (5-ALA)75 or fluorescein76 in tumor tissue. New advanced 
contrast agents that enable multi-modal imaging of the same probe before and during 
surgery hold great promise with higher resolution, sensitivity and specificity than 
conventional technologies, and can also be exploited for drug delivery or phototermal 
therapy of brain tumors77. 
 
 
Figure 3 Preoperative outlines of a tumor and functional structures. 3D volumetric rendering 
of an occipital brain metastasis from lung adenocarcinoma and the adjacent venous sinuses 
using BrainLab® (Brainlab AG). Illustration by T. Sundstrøm. 
 
Numerous studies have been performed on image-guided surgery for the resection of 
brain tumors, but a recent Cochrane review only identified four RCTs of sufficient 
quality78: one study for intraoperative MRI79, one study for fluorescence-guided 
surgery80 and two studies for neuronavigation81,82. No studies on US-guided surgery 
were deemed eligible for inclusion; 3D US-guided surgery (Sonowand®)83 has not 
yet been the subject of a RCT. The Cochrane review concluded that although each of 
these technologies have their merits like increased extent of resection, the quality of 
evidence is poor, effects on survival and quality of life are uncertain and studies suffer 
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from significant reporting biases78. Thus, further research is needed to determine the 
efficacy of these techniques and their individual applicability. Moreover, most of 
these studies were conducted in patients with high- or low-grade gliomas, hence, the 
value of these imaging resources are even less clear in brain metastasis surgery. For 
example, fluorescence-guided resection using 5-ALA does not seem to be reliable in 
identifying infiltrating parts of metastases75. 
 
Although surgery plays an indispensable role in the treatment of brain metastases, it is 
not enough73. Local recurrence rates after gross-total resection without subsequent 
WBRT are about 50-60% with current surgical standards84,85. This can of course be 
ascribed to the surgery itself (e.g. inadequately performed, tumor cell dissemination), 
but is more likely related to the nature of the disease. For example, cumulative 
evidence suggests that brain metastases are not as circumscribed and sharply 
demarcated as we have thought. In an autopsy study, 63% of patients displayed 
invasive growth patterns, and this was most common with SCLC and melanoma86. In 
a recent surgical series, more than 60% of patients showed tumor extensions and islets 
in the adjacent brain parenchyma75. Taken together, brain metastases should 
preferentially be resected en bloc, there may be a role for supramarginal resection in 
selected patients and surgery should be combined with SRS or WBRT73. 
 
4.2.3.2. Whole brain radiotherapy 
WBRT has historically been the major alternative to surgical treatment of brain 
metastases87. A landmark paper published in 1954 showed that radiotherapy alleviated 
symptoms in 63% of patients and provided similar responses in tumors assumed to be 
radiosensitive as well as radioresistant (e.g. melanoma)88. By the 1970s, WBRT had 
become a mainstay therapy for brain metastases89. Moreover, radiotherapy was at the 
time found to be associated with minimal morbidity and toxicity90. WBRT is still a 
standard of care in combination with other treatments, and it remains the treatment of 
choice for patients with multiple brain metastases, addressing both macroscopic and 
microscopic disease91. 
 
However, there are growing concerns about the adverse effects of WBRT, especially 
the long-term effects of neurocognitive decline and reduced quality of life92-94. WBRT 
 27 
alone is inadequate over time; in an analysis of 1,200 patients treated with WBRT 
alone between 1979 and 1993, even the best prognostic group was found to have a 
median survival of just 7.1 months95. Moreover, systemic treatments have 
progressively improved since the mid-1970s, and the mortality rates of most cancers 
have decreased, even among patients with metastatic disease96. Hence, patients live 
longer, and the long-term adverse effects of WBRT have gradually become more 
apparent. 
 
Different dose-fractionation schedules have been utilized in numerous studies, but the 
most common treatment schedule for WBRT is 30 Gy delivered in 10 fractions over 
two weeks91. This protocol is generally accepted to provide the best trade-off between 
efficacy and toxicity. WBRT-toxicities are typically classified as acute (within a few 
days), early-delayed (first weeks to months) or late (after 90 days)91. In the acute 
phase, patients frequently experience fatigue, nausea/vomiting, alopecia, dermatitis 
and steroid-responsive cerebral edema. Early-delayed symptoms include fatigue and 
neurocognitive deficits such as memory decline. The late-stage toxicities are usually 
not self-limited and mild as in the acute and early-delayed stages. The classical 
biphasic pattern of neurocognitive deterioration begins with a decline around four 
months after treatment, thereafter a transient improvement before the patients 
irreversibly deteriorate months to years later with moderate to severe dementia17,97. 
 
Although various dose-fractionation schedules have failed to demonstrate improved 
tumor control and patient survival in patients with brain metastases, randomized trials 
with WBRT in combination with surgery36,61,62 or SRS98,99 have. The studies by 
Patchell et al., Vecht et al. and Noordijk et al. are discussed above36,61,62. The 
Radiation Therapy Oncology Group (RTOG) 9508 phase III randomized trial 
compared the use of WBRT with or without SRS for patients with one to three brain 
metastases98. This study showed a significant benefit in OS of adding SRS (6.5 
months versus 4.9 months) and a stable/better Karnofsky Performance Status (KPS) at 
six months (43% versus 27%); however, patients with multiple brain metastases did 
not have better survival, but better KPS scores and less steroid use. For patients with 
two to four brain metastases, Kondziolka et al. reported a one-year local failure rate of 
100% with WBRT alone, but only 8% with the addition of SRS; median time to local 
failure was six months versus 36 months, respectively99. This study also showed a 
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non-significant survival benefit of adding SRS to WBRT (7.5 months versus 11 
months). 
 
In a randomized trial of prophylactic cranial irradiation or not in 286 patients with 
extensive SCLC, Slotman et al. found that irradiation resulted in an improvement in 
median survival from 5.4 months to 6.7 months and a reduced risk of symptomatic 
brain metastases within one year from 40.4% to 14.6%100. Irradiation had side effects, 
but there were no significant differences in global health status between the two 
groups. In contrast, in a randomized trial by Gore et al., including 356 patients with 
advanced NSCLC, prophylactic cranial irradiation was not associated with improved 
one-year OS, even though there was a 2.5 times higher risk of developing brain 
metastases without irradiation101. In this study, the patients showed a considerable 
neurocognitive decline, although they received a lower dose of WBRT (30 Gy in 15 
fractions) than standard. 
 
Several strategies have been investigated to reduce the neurocognitive impact of 
WBRT. The results of a phase II trial of WBRT with hippocampal sparing were 
recently reported by Gondi et al. who found significantly less impairment of memory 
function and quality of life compared with historical series102. This technique has also 
been developed to selectively expose metastatic lesions to higher radiation doses 
(integrated brain metastases boost)103, and there are currently several ongoing clinical 
trials that aim to evaluate this composite technology. Memantine, a N-methyl-D-
aspartate (NMDA) receptor antagonist, which is used to treat patients with Alzheimer 
disease, was recently evaluated in a randomized trial of 508 patients with brain 
metastases receiving WBRT104. Compared to placebo, memantine significantly 
delayed and reduced neurocognitive deterioration, but did not affect survival (see 
Paper IV). 
 
The combination of WBRT and conventional chemotherapies that can penetrate the 
BBB has generally produced discouraging results17. One of the best studied 
chemotherapeutic agents that can cross the BBB is the lipid soluble and alkylating 
agent temozolomide (TMZ). Taken together, the combination of WBRT and TMZ has 
shown limited or no benefit compared to WBRT alone in four phase II clinical 
trials105-108. 
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The use of targeted drugs rather than traditional chemotherapeutic agents is regarded 
as a more promising approach with reduced systemic toxicity and higher potential for 
individual stratification of patients to effective therapies17. Welsh et al. recently 
published a phase II trial on 40 patients with NSCLC with brain metastases that were 
treated with WBRT + the epidermal growth factor receptor (EGFR) inhibitor 
erlotinib109. The authors reported an 86% response rate, few adverse effects and a 
median survival of 11.8 months; subgroup analyses revealed a median survival of 
19.1 months for patients with EGFR mutations and 9.3 months for patients with wild-
type EGFR. In contrast, Sperduto et al. found a median survival of 13.4 months for 
WBRT + SRS, 6.3 months for WBRT + SRS + TMZ, and 6.1 months for WBRT + 
SRS + erlotinib in 126 NSCLC patients with one to three brain metastases110. These 
survival differences were not statistically significant, and, importantly, subgroup 
allocation was not biomarker-based and the control group (WBRT + SRS) displayed 
much better outcomes than anticipated from previous reports: 6.5 months98 and 7.5 
months111. In summary, combinatorial regimens of WBRT, SRS, chemotherapeutic 
drugs and molecularly targeted drugs for patients with brain metastases are a subject 
of intense research, and there is a need to define relevant subgroups of patients that 
adequately benefit from the various combinations. 
 
4.2.3.3. Stereotactic radiosurgery 
Noninvasive ablation of cancer cells using focused, high-dose radiation is an option to 
surgical resection. SRS can be delivered with a Gamma Knife (gamma rays) or a 
linear accelerator (LINAC; X-rays), and is a non-invasive technique that treats the 
tumor with minimal radiation exposure to the surrounding healthy tissue. Treatment 
of brain tumors, including metastases, is typically completed in a single session of 30-
60 minutes. In contrast, conventional radiotherapy typically involves multiple 
sessions and does not spare the surrounding tissue. Table 1 shows some key SRS 
studies from the last decade. 
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Table 1 Selected studies of SRS treatment of brain metastases. 
Study Pts Mets Dose (Gy) Treatment Local 
control 
(%) 
 
OS 
(months) 
Sneed112 559 1 to ≥4 NR SRS+WBRT vs SRS 9/8 NR 
Andrews98 333 1-3 15-24 WBRT vs WBRT+SRS 71/82 4.9/6.5 
Aoyama111 132 1-4 18-25 SRS+WBRT vs SRS 89/73 8/7.5 
Muacevic113 64 1 14-27 S+WBRT vs SRS 82/97 9.5/10.3 
Soltys114 72 1-4 15-30 S+SRS 79 NR 
Brennan115 49 1-2 15-22 S+SRS 78 NR 
Serizawa116 778 1-10 13.5-30 SRS 78-98 NR 
Kocher117 359 1-3 ≥20 S/SRS+WBRT vs S/SRS NR 11/11 
Minniti118 101 1 9 x 3 
fractions 
S+SRS 93 17 
Abbreviations: S, surgery; SRS, stereotactic radiosurgery; WBRT, whole brain radiotherapy; 
OS, median overall survival; NR, not reported; Mets, number of metastases; Pts, number of 
patients. 
 
SRS has been recommended as the preferred treatment for patients with a limited 
number of brain metastases and an overall good prognosis112,119. In a RCT of 132 
patients with one to four brain metastases less than three centimeters in diameter, 
Aoyama et al. found a similar median survival for SRS alone (8 months) compared to 
WBRT + SRS (7.5 months). However, there were significantly more tumor 
recurrences for SRS alone (76.4%) versus WBRT + SRS (46.8%), and salvage 
therapy was frequently needed in patients that were not treated with up-front 
WBRT111. Chang et al. specifically addressed the benefits and neurocognitive risks 
from adding WBRT to SRS in 58 patients with one to three brain metastases120. The 
trial was stopped early by the data monitoring committee due to a significantly greater 
risk of decline in memory and learning function for patients randomized to WBRT + 
SRS. The authors found a median survival of 15.2 months for SRS alone and 5.7 
months for WBRT + SRS, and a local tumor control rate of 67% in the SRS group 
and 100% in the WBRT + SRS group. In a meta-analysis of RCTs evaluating SRS, 
WBRT or both for patients with a limited number of brain metastases, Tsao et al. 
could not find a difference in OS, SRS alone was associated with a better 
neurocognitive outcome and performance status, and WBRT + SRS was superior in 
providing both local tumor control and distant brain control121. Conclusively, 
although the addition of WBRT to SRS provides better disease control, patients are 
probably better off with SRS alone and vigilant control when it comes to 
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neurocognitive function, performance status and quality of life84,121,122. Patients 
initially treated with SRS alone who experience local or distant relapse should 
preferably undergo salvage therapy with SRS or WBRT, as OS is similar to that of 
patients initially treated with WBRT + SRS121. 
 
It is generally accepted that SRS alone can be considered in patients with more than 
three brain metastases, and WBRT should still be considered for patients with less 
than four brain metastases. Interestingly, a recent paper from Japan investigated the 
efficacy of SRS without WBRT for patients with multiple brain metastases; median 
survival was 13.9 months for 455 patients with one brain metastasis, 10.8 months for 
531 patients with two to four brain metastases, and 10.8 months for 208 patients with 
five to 10 brain metastases123. Survival differences were not significant between 
patients with two to four and five to 10 tumors, and the authors concluded that SRS 
might be a valid option instead of WBRT in patients with up to 10 metastases. In a 
multi-institutional series of 1,921 gamma knife-treated patients between 1975 and 
2007, Karlsson et al. found patient age and primary tumor control to be more 
important predictors of survival than the number of brain metastases; 25 patients 
survived for more than 10 years124 (Fig. 4). 
 
 
Figure 4 Long-term survivor after gamma knife 
treatment of multiple brain metastases. This 
patient underwent gamma knife surgery for nine 
metastatic lesions in 1994 (top; MRI T1-
weighted with contrast enhancement), and was 
alive and tumor-free at the latest follow-up in 
2005 (bottom; MRI FLAIR images showing 
only a local high signal reminiscent of previous 
treatment). Reproduced with permission from 
Karlsson et al.124. 
 
Currently, there are no available studies with Level I evidence that compare surgery 
to SRS, or surgery + SRS to surgery + WBRT (the NCT01372774 trial is currently 
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recruiting patients to answer the latter issue)17. A recent Cochrane review of surgery 
or SRS + WBRT versus surgery or SRS alone identified five RCTs63,84,111,120,125, and 
found that up-front WBRT reduced the risk of brain relapse at one year by 53%, but 
there was no clear difference in OS or progression-free survival (PFS)126. The effects 
on OS were similar between surgery and SRS, among different WBRT protocols and 
independent of the number of brain metastases. Study biases and methodological 
inconsistencies made it difficult to determine whether up-front WBRT had a negative 
impact on neurocognitive function and quality of life. Moreover, there was only low 
quality evidence favoring up-front WBRT to surgery and SRS in reducing brain 
relapse. Nevertheless, there is ample and robust documentation to guide us in clinical 
decision-making for surgery, SRS and/or WBRT in patients with brain metastases. 
 
4.2.3.4. Systemic therapy 
Future advances in brain metastasis therapy will most likely come from improvements 
in systemic therapy. However, there is currently no Level I evidence comparing 
systemic therapy to surgery or radiation in the management of brain metastases127. 
Patients with brain metastases are often excluded from clinical trials44-46. Brain 
metastasis patients have frequently been subjected to a range of previous treatments at 
the time of diagnosis and the tumors might already be resistant to targeted therapies 
when they need them the most127. Randomized studies that are focused on brain 
metastases are scarce and often small with variable endpoints127. Furthermore, 
preclinical data clearly indicate that chemotherapeutic and molecularly targeted 
agents are better at preventing brain metastases than shrinking macroscopic lesions5. 
Preservation of neurological structures and function is unquestionably the best 
strategy, but preventive treatment also raises a number of controversies around patient 
eligibility, resistance development, toxicity issues and clinical trial design that remain 
to be resolved. 
 
At present, there is no standard cytotoxic chemotherapy for the treatment of brain 
metastases17. Brain metastases that cannot be controlled with surgery or radiotherapy 
are therefore treated with the same cytotoxic chemotherapies used to treat extracranial 
disease. Some agents known to penetrate the BBB, such as TMZ, procarbazine, 
irinotecan, topotecan and carboplatin, are also employed on an empirical basis for the 
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treatment of brain metastases, even if these agents are not considered standard 
therapies for the primary cancer per se. A recent review of 21 clinical trials 
investigating the use of TMZ in patients with brain metastases revealed variable but 
better response rates when TMZ was combined with WBRT (8.8-95.9%) and/or other 
anticancer drugs (0-42.8%), as compared to single agent TMZ therapy (4.2-10%)128. 
 
Molecularly targeted therapies have already become established treatments for 
subgroups of patients with specific molecular drivers of cancer progression. 
Approximately 50% of melanoma patients have activating mutations in the BRAF 
gene, and the serine/threonine-protein kinase B-raf (BRAF) inhibitors vemurafenib 
and dabrafenib have been shown to produce tumor regression and improved survival 
in BRAF-mutated patients with metastatic melanoma129,130 (Fig. 5). 
 
 
Figure 5 A 38-year-old patient with BRAF-mutant melanoma and subcutaneous metastases. 
Photographs were taken (A) before initiation of vemurafenib, (B) after 15 weeks of therapy 
with vemurafenib, and (C) after relapse, after 23 weeks of therapy. Reproduced with 
permission from Wagle et al.138. 
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The ERBB2 gene, which encodes the growth factor receptor HER2, is amplified and 
HER2 is overexpressed in about 30% of patients with breast cancer; trastuzumab, a 
HER2 monoclonal antibody, has been found to prevent tumor progression and 
prolong survival in such patients with metastatic disease131. Activating mutations in 
the EGFR gene are present in approximately 10-60% of patients with NSCLC, and 
the EGFR inhibitors erlotinib and gefitinib have been shown to restrain tumor 
progression and improve survival in patients with EGFR-mutated metastatic 
NSCLC132,133. Furthermore, about 5% of patients with NSCLC have activating 
rearrangements in the ALK gene, and the anaplastic lymphoma kinase (ALK) 
inhibitors ceritinib and crizotinib have been shown to produce tumor regression and 
increase PFS in patients with metastatic NSCLC and ALK-rearrangements134,135. 
 
At present, there are about 40 different monoclonal antibodies or protein kinase 
inhibitors in the Norwegian Pharmaceutical Product Compendium (Felleskatalogen 
AS), and this list is steadily increasing. Continued advancements in molecular 
characterization and development of targeted therapies for various cancers will 
undoubtedly have important ramifications for brain metastasis. Some of the molecular 
drivers identified are even associated with an increased propensity of brain metastasis, 
and the development of specific inhibitors is therefore especially warranted. Patients 
with advanced HER2-positive breast cancer have for example a 30-50% risk of 
developing brain metastases, but trastuzumab with a molecular weight of about 148 
kDa is unable to penetrate the BBB and is ineffective in treating established brain 
metastases136,137. Survival improvements associated with the profound extracranial 
responses of molecularly targeted drugs increases the patients’ time at risk of 
developing brain metastases, and the specific activity of these drugs against brain 
metastases is an increasingly relevant issue of future research. 
 
Systemic drug therapy of brain metastases has a number of challenges. A key 
challenge is the poor bioavailability of drugs due to the presence of the BBB at the 
level of the brain vascular endothelium139. Moreover, cancer cells that have 
extravasated to the brain parenchyma, but not yet developed into a macroscopic 
tumor, might find protection beyond the BBB (“sanctuary site”) or be more prone to 
develop resistance due to sub-therapeutic drug concentrations. The BBB has low 
passive permeability and expresses high levels of efflux transporters, which together 
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limit the penetration of drugs and their ability to reach therapeutic concentrations in 
the brain140,141. Examples of drugs with limited ability to cross the BBB include 
trastuzumab with its high molecular weight, and paclitaxel and doxorubicin, which 
are excluded from the brain by efflux transporters142,143. The BBB and the BBB 
around brain tumors – the blood-tumor-barrier (BTB) – is discussed in further detail 
in section 4.4.2.4. 
 
Corticosteroids are an integral part of the clinical management of brain metastases, 
and dexamethasone is the drug of choice due to its limited mineralocorticoid 
effects144,145. Dexamethasone effectively reduces peritumoral edema within 24-72 
hours in up to 75% of patients144, and is recommended to provide temporary 
symptomatic relief from increased intracranial pressure and focal mass effect145. 
Corticosteroids should be tapered slowly over two weeks or more in symptomatic 
patients. 
 
Lung cancer, breast cancer and melanoma are the most common causes of brain 
metastases, but also the cancers that have seen the greatest advances in targeted 
therapies over the last decade17,127. The main findings from some of the most 
influential clinical studies of systemic therapies for patients with brain metastases 
from lung cancer, breast cancer and melanoma over the last 10 years are summarized 
in Tables 2-4. At present, there are 557 open studies on brain metastasis at 
ClinicalTrials.gov (U.S. National Institutes of Health). Most of these studies involve 
novel systemic therapies or combinatorial regimens. 
 
4.2.3.4.1. Lung cancer brain metastases 
Lung cancer is the most common cause of brain metastases, and approximately 40% 
of patients with NSCLC develop brain metastases146. Chemotherapeutic regimens 
with platinum-based drugs as up-front therapy of brain metastases have shown 
response rates between 28% and 45%147-152. Two small patient series of recurrent or 
progressive NSCLC brain metastases reported objective responses of TMZ in 2/22153 
and 3/30 patients154. The multitarget antifolate pemetrexed alone showed a 38.4% 
response rate in patients with recurrent disease155, and first-line therapy with 
pemetrexed and cisplatin showed a 41.9% response rate156. 
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SCLC represents 13% of lung cancer cases and more than 90% of patients are elderly 
smokers157. The treatment of choice is chemo- and radiotherapy, including 
consideration of prophylactic cranial irradiation; 24% of SCLC patients have brain 
metastases at diagnosis. In contrast to NSCLC, SCLC is not associated with a specific 
somatic mutation. 
 
Targeted therapy of NSCLC has become increasingly important over the last 10 years. 
EGFR mutations are present in 10-60% of patients; non-smokers, adenocarcinomas, 
females and Asian individuals have the highest mutation frequencies158-160. The 
presence of EGFR mutations in tumors and cell lines are predictive of sensitivity to 
the EGFR inhibitors gefitinib and erlotinib158,161. However, the mutation status of a 
primary tumor does not necessarily reflect that of the corresponding metastasis, and 
this can have important implications for both diagnostics (new biopsy?) and treatment 
(new round or different drug?). For example, in a comparative analysis of EGFR 
mutation status in NSCLC primary lung tumors and metastases, Gow et al. reported 
that 9/18 patients had lost the mutation in their metastasis, whereas 17/26 had gained 
the mutation in their metastases; 7/17 patients that had transformed from EGFR wild-
type to EGFR mutation positive had brain metastases162. 
 
EGFR inhibitors have been tested in both naïve and recurrent brain metastases from 
NSCLC with findings that reflect the underlying genetic makeup (Tab. 2). Ceresoli et 
al. reported a 10% response rate of gefitinib in heavily pretreated and unselected 
Italian patients163. In contrast, Hotta et al. found a 43% response rate in a Japanese 
population of 50% non-smokers164, and Wu et al. found a 32% response rate in 
Chinese non-smokers165, both with recurrent brain disease and undetermined EGFR 
mutation status. Small prospective studies of gefitinib and erlotinib in unselected 
Asian patients with newly diagnosed brain metastases have also shown encouraging 
response rates of 50%166 and 73.9%167. An 81% response rate was observed in 
Chinese patients with unknown EGFR mutation status when WBRT was added to 
gefitinib168. In another study, an 82.4% response rate was noted from WBRT and 
erlotinib in EGFR mutation positive patients; notably, this study also featured 36 
patients without EGFR mutations and none of these patients were responders169. Two 
other small series have also shown promising responses of erlotinib monotherapy in 
mutated patients170,171. In a recent phase II study of WBRT + erlotinib in both 
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pretreated and untreated US patients, Welsh et al. reported an 86% response rate; 
subgroups of patients with and without EGFR mutations had response rates of 89% 
and 63%, respectively109. In contrast, in a recent RCT of WBRT versus WBRT + 
erlotinib in English patients with treatment-naïve NSCLC brain metastases and 
undetermined EGFR status, Lee et al. failed to demonstrate an improvement in PFS or 
OS172. Interestingly, in a RCT of WBRT + SRS with or without TMZ or erlotinib in 
unselected, newly diagnosed patients, Sperduto et al. observed a reduction in survival 
with the addition of either systemic agent, which could possibly reflect deleterious 
toxicity110. Taken together, these studies suggest that EGFR inhibitors should be 
reserved for patients with EGFR mutations. 
 
Rearrangements in the ALK gene are present in 2-7% of patients with NSCLC and 
predict response to the ALK inhibitors crizotinib135,173,174, ceritinib134 and alectinib175. 
ALK rearrangements are more frequently seen in young patients, non-smokers and 
adenocarcinomas174. In a study by Preusser et al., ALK translocations were found to 
be constant between 16 matched primary tumors and brain metastases176. In a 
randomized trial of crizotinib versus chemotherapy (permetrexed/docetaxel) in ALK-
positive patients with advanced disease, 35% and 34% of patients had brain 
metastases, respectively174. Overall response rates were significantly better with 
crizotinib (65% versus 20%), but there was no difference in OS. Costa et al. recently 
presented a retrospective review of 888 crizotinib-treated ALK-positive patients of 
which 275 patients had brain metastases at enrolment177. Crizotinib was effective in 
both newly diagnosed (response rate 18%) and pretreated (radiotherapy; response rate 
33%) patients. Twenty percent of patients without brain metastases at inclusion were 
diagnosed with brain metastases while on crizotinib. 
 
4.2.3.4.2. Breast cancer brain metastases 
Historical series show that 10-30% of patients with breast cancer develop brain 
metastases178. Advances in systemic therapy for breast cancer have resulted in 
improved survival179, and as patients are living longer, more patients eventually 
develop brain metastases during the course of their disease19. Younger age, HER2 
mutation status, hormone receptor status (estrogen receptor (ER) and progesterone 
receptor (PR)), and presence of lung metastases are associated with an increased risk 
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of developing brain metastases179,180. Conventional chemotherapeutic regimens using 
cyclophosphamide, 5-fluorouracil, methotrexate, vincristine and/or doxorubicin have 
shown intracranial response rates between 17% and 76%181,182. Combinatorial 
treatment with cisplatin and etoposide has induced response rates of 38-55%151,183. 
Case reports and small patient series have shown some efficacy of capecitabine184 or 
topotecan185 monotherapy. 
 
Targeted agents have become key elements in the contemporary management of 
advanced breast cancer. Brain metastases develop in 29-37% of patients with HER2-
positive breast cancer179,186,187. Breast cancer patients who overexpress HER2 benefit 
from targeted treatment with trastuzumab188, but trastuzumab has poor CNS 
penetration and its survival advantages have largely been ascribed to control of 
extracranial disease189. However, positron emission tomography (PET) imaging 
studies of isotope-labeled trastuzumab in patients with metastatic breast cancer have 
shown a higher uptake than previously appreciated in brain metastases190. 
Furthermore, and as discussed for EGFR-mutated NSCLC, the mutation status of 
primary tumors and brain metastases is not always concordant and can have important 
implications for clinical management and prognosis. Duchnowska et al. investigated 
HER2, ER and PR expression of 120 matched primary breast cancers and brain 
metastases, and HER2 expression was lost in 12% and gained in 16% of brain 
metastases, whereas ER and PR was lost in 43% and 56% and gained in 19% and 
14% of brain metastases, respectively191. 
 
Kirsch et al. showed that trastuzumab treatment more than doubled the OS of patients 
with HER2-overexpressing brain metastases189. However, the OS of patients with 
HER2-negative tumors was similar to that of patients with HER2-positive tumors that 
did not receive trastuzumab (Tab. 3). Two recent case reports have shown regression 
of HER2-positive brain metastases with trastuzumab emtansine (T-DM1)192,193, an 
antibody-drug conjugate of trastuzumab and the cytotoxic agent mertansine (DM1); 
T-DM1 is currently being evaluated in clinical trials. 
 
Lapatinib, an inhibitor of HER2 and EGFR, combined with capecitabine is used for 
advanced HER2-positive breast cancer that has progressed on trastuzumab. Lapatinib 
was the first HER2-directed drug to be validated in a preclinical brain metastasis 
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model194, but has shown a rather discouraging 6% response rate as monotherapy in 
patients with recurrent HER2-positive breast cancer brain metastases195. Better 
intracranial responses have been seen when lapatinib is combined with capecitabine in 
patients with HER2-positive brain metastases: 20% in recurrent195 and 65% in 
treatment-naïve patients196. An OS of 11.3-17 months has been reported with this 
combined therapy196,197, though with a 49% frequency of grade 3 and 4 adverse 
events196. Lin et al. recently reported a 79% response rate of lapatinib and WBRT in 
HER2-positive brain metastases198. In a study of Asian HER2-positive breast cancer 
patients with brain metastases, OS was 10.5, 21.4 and 25.9 months with trastuzumab 
alone, lapatinib alone and trastuzumab + lapatinib, respectively199. 
 
In a study by Lin et al. of 116 patients with metastatic triple-negative breast cancer 
(HER2-, ER- and PR-negative), almost half of the patients developed brain metastases 
and median OS was only 4.9 months200. In contrast to HER2-positive disease, triple-
negative patients with brain metastases usually succumb to progressive extracranial 
disease regardless of the frequent CNS involvement. Therapeutic advances in triple-
negative breast cancer have been unsuccessful and there is great need for targeted 
agents that can control both intracranial and extracranial disease200. Phosphatase and 
tensin homolog (PTEN) loss is present in up to 60% of triple-negative brain 
metastases and has been associated with a more aggressive disease course201,202. 
Ongoing studies are looking at agents that target the PTEN-Phosphoinositide 3-kinase 
(PI3K)-Protein kinase B (AKT) pathway in breast cancer. 
 
In a recent prospective study of bevacizumab (inhibitor of vascular endothelial growth 
factor (VEGF)) + WBRT treatment of 19 patients (13 with breast cancer) with newly 
diagnosed brain metastases, Lévy et al. reported intracranial responses in 10 patients 
at three months; there was a trend towards better responses with higher doses of 
bevacizumab203. Combination treatment with trastuzumab, lapatinib and bevacizumab 
has also shown intracranial efficacy in heavily pretreated HER2-positive patients204. 
In a small study of four patients with breast cancer brain metastases, all patients 
responded to treatment with paclitaxel + bevacizumab205. Several other studies have 
reported substantial responses with various combinatorial regimens that include 
bevacizumab, but reduced contrast enhancement and/or edema may not be true 
surrogates of tumor response206. 
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4.2.3.4.3. Melanoma brain metastases 
Brain metastases are diagnosed in 10-40% and found in up to 75% of melanoma 
patients on autopsy207-217. Multiple brain metastases are present in 50-70% of 
patients23,215-217. Other organ metastases are seen in 50-80% of patients210,216,218. An 
increasing number of patients are diagnosed with asymptomatic brain metastases; 30-
60% of patients in clinical and autopsy series210,215,219,220. Spontaneous hemorrhage 
occurs in 10-40% of lesions212,214,218,221. The median time from the diagnosis of 
melanoma to the diagnosis of brain metastases was 3.7 years in two large patient 
series216,222. Treatment is the major determinant of survival and patient selection is the 
major determinant of treatment31,216,222.  
 
Importantly, although a number of clinical trials have been conducted in patients with 
brain metastases, no prospective RCTs of local therapies (SRS, WBRT or surgery) 
have been conducted in the melanoma population223. 
 
For many years, no conventional chemotherapy or targeted agent were shown to 
improve OS in patients with metastatic melanoma in phase III RCTs224,225. Traditional 
chemotherapy regimens with dacarbazine were associated with an overall response 
rate of only 15%226, and its efficacy in patients with brain metastases was even 
lower227. TMZ, an oral analogue of dacarbazine with excellent brain penetration, was 
widely used over the first decade of the 21st century. However, therapeutic responses 
of TMZ were modest at best228-230. 
 
 
Figure 6 Vemurafenib for melanoma brain 
metastases. Brain MRI (A,B) before and (C,D) after 
six months of treatment with vemurafenib. Modified 
with permission from Rochet et al. 2011231. Copyright 
Massachusetts Medical Society. 
A B
C D
 41 
In 2002, Davies et al. reported that 66% of melanomas harbor mutations in the BRAF 
oncogene, which results in activation of the mitogen-activated protein kinase (MAPK) 
pathway232. This discovery initiated a hunt for pertinent therapeutics as well as other 
molecular aberrations in metastatic melanoma, and since 2011 we have seen a 
therapeutic revolution with the clinical development of MAPK-targeted therapies 
(BRAF inhibitors vemurafenib and dabrafenib, and mitogen-activated protein kinase 
kinase (MEK) inhibitor trametinib)233 (Fig. 6). In parallel, we have witnessed 
considerable advances in immunotherapy with the introduction of immune checkpoint 
inhibitors (antibodies against cytotoxic T-lymphocyte-associated protein 4 (anti-
CTLA-4; ipilimumab) and programmed cell death protein 1 (anti-PD-1; 
pembrolizumab and nivolumab)). In brief, MAPK-targeted treatments and immune 
checkpoint inhibitors have shown impressive antitumor effects in subgroups of 
patients with metastatic melanoma, but gains in OS are generally modest (Tab. 7); the 
survival benefits for patients with brain metastases are even more discouraging (Tab. 
4). Treatment responses are usually short-lived due to resistance development, and 
many of these therapies are also significantly hampered by side effects both as 
monotherapies and as combinatorial regimens233,234. We still have a long way to go, as 
we consider this genetically heterogeneous disease as a whole, and particularly the 
unmet needs of patients with melanoma brain metastases47,224,225. 
 
Melanoma therapy and the biology of melanoma brain metastasis are discussed in 
further detail in sections 4.3 and 4.4. 
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4.2.4. Prognosis 
Patients with brain metastases generally have a dismal prognosis. Left untreated, 
patients survive on average 1-2 months after diagnosis216,222,247-249. Patient survival is 
dependent on multiple variables: the brain metastases per se (size, number, location), 
but also the cancer (histology, disease stage, treatment response), the patient (age, 
performance status, co-morbidity), the doctor (diagnostics, treatment, follow-up) and 
the goals of care (patient and physician preferences). Several prognostic indices have 
been published; the most influential have been the RTOG recursive partitioning 
analysis (RPA)95 and the graded prognostic assessment (GPA)250. Rodrigues et al. 
recently published a systematic review of prognostic systems for patients with brain 
metastases, and concluded that the ideal prognostic index had yet to be defined251. 
However, in contrast to the GPA index, the RTOG RPA is not diagnosis-specific and 
does not reflect current advances in systemic therapy252. 
 
 
Figure 7 Historical survival curves for prognostic factors in patients with brain metastases. 
(A) Treatment modality (surgery + radiotherapy, radiotherapy and steroids). (B) Performance 
status at diagnosis. Eastern Cooperative Oncology Group (ECOG) performance status: 0 = 
asymptomatic; 1 = symptomatic, but completely ambulatory; 2 = symptomatic, <50% in bed 
during the day; 3 = symptomatic, >50% in bed, but not bedbound. (C) Systemic tumor burden 
(none, limited and extensive). (D) Response to steroid treatment (good, moderate and 
little/no). Reprinted with permission from Lagerwaard et al.31. 
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Lagerwaard et al. investigated prognostic factors in 1,296 patients with brain 
metastases, treated in a single institution in the Netherlands between 1981 and 199031. 
Treatment modality, performance status at diagnosis, systemic tumor burden and 
response to steroid treatment had the strongest impact on survival (Fig. 7). Gaspar et 
al. reported similar findings in a series of 1,200 patients with brain metastases95. Both 
studies also confirmed a significantly negative impact of higher age. Interestingly, 
19% of patients in Lagerwaard et al.’s study were ≥70 years of age31, and this subset 
of patients is increasing. Taken together, although these patients were treated in the 
1980s and before the era of molecularly targeted agents, these data are still highly 
relevant today. They provide a good overview of what can be achieved with the 
different treatments that are available and which patients are most likely to benefit 
from aggressive therapies. Unfortunately, they also suggest that even though new 
systemic therapy has induced substantial intracranial responses and improved PFS, 
OS is largely the same now as in the 1980s and 90s. Diagnosis-specific prognostic 
factors and median survival with different treatment combinations for NSCLC, 
SCLC, melanoma, renal cell carcinoma, breast cancer and gastrointestinal cancer, 
adapted from a large retrospective study of 3,809 patients with brain metastases are 
provided253 (Tab. 5). 
 
In a recent patient series from a multi-disciplinary brain metastasis clinic, 114 patients 
with oligometastatic disease and good performance status showed a median survival 
of 16 months (two-year survival 31.5%)254. The median survival was 12 months for 
surgery, 16 months for surgery + WBRT, 13 months for SRS and 23 months for 
WBRT. Patients were initially treated with surgery (52%), WBRT (23%), SRS (14%), 
surgery + WBRT (9%) and supportive care (2%). Twenty-five percent of patients 
developed local relapse, 11% developed distant relapse and 15% developed both local 
and distant relapse. Second-line treatment was WBRT (21%), SRS (13%) and surgery 
(9%). This study shows what can be achieved with careful patient selection and multi-
disciplinary management within a dedicated joint neurosurgical/neuro-oncology 
clinic. 
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Table 5 Prognostic factors and median survival for 3,809 patients with newly diagnosed brain 
metastases treated between 1985 and 2007. 
 Median survival 
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W
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T+
SR
S 
NSCLC 1888 Age 
KPS 
ECM 
No 
7.00 3.42 9.92 12.59 11.86 11.66 12.06 
SCLC 299 KPS 
ECM 
No 
4.90 3.87 6.90 15.23 12.02 14.66 14.95 
Melanoma 483 KPS 
No 
6.74 2.86 7.26 6.67 12.78 11.10 13.11 
Renal cell 
carcinoma 
286 KPS 
No 
9.63 5.08 10.78 12.12 12.91 15.52 8.80 
Breast cancer 642 KPS 11.93 5.55 13.80 15.47 21.68 18.23 15.80 
GI cancer 211 KPS 5.36 2.92 7.33 7.13 9.76 10.37 7.92 
Abbreviations: NSCLC, non-small cell lung cancer. SCLC, small cell lung cancer. GI cancer, 
gastrointestinal cancer. KPS, Karnofsky performance status. ECM, extracranial metastases. 
No, number of brain metastases. WBRT, whole brain radiotherapy. SRS, stereotactic 
radiosurgery. S, surgery. Prognostic factors: Multivariate analysis of diagnosis-specific 
factors (P < 0.05). Adapted from Sperduto et al. 2010253. 
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4.3. MELANOMA 
 
4.3.1. Melanoma: a poster child for personalized medicine 
Melanoma is the most deadly form of skin cancer. Over the last decade, major 
progress has been made in our biologic understanding of melanoma and this has been 
directly translated into new therapies. Melanoma has become a poster child for 
personalized medicine with the parallel clinical development of molecularly targeted 
therapies and immunotherapies. 
 
For localized melanoma and regional lymph node metastases, surgery remains the 
standard of care234. Precise disease staging can be achieved with sentinel-node biopsy 
and non-sentinel lymph node dissection, but this has not been shown to affect survival 
in prospective series255-257. 
 
4.3.2. Epidemiology and risk factors 
The incidence of melanoma is increasing and death rates continue to rise258-260. In the 
US, melanoma was the fifth most common cancer in 2014, accounting for 4.6% of all 
new cancer cases and 1.7% of all cancer deaths (Tab. 6). The rates for new melanoma 
cases in the US have been rising on average 1.8% each year over the last 10 yearsa. 
 
Table 6 Melanoma epidemiology in the United States.  
Number of new cases per 100,000 per year (total)# 21.3 (76,100) 
 Men 27.7 
 Women 16.7 
Median age in years at diagnosis# 62 
Number of deaths per 100,000 per year (total)# 2.7 (9,710) 
 Men 4.1 
 Women 1.7 
Median age in years at death# 69 
5-year survival§ 91.3% 
 Localized – confined to primary site (84%$) 98.1% 
Regional – spread to regional lymph nodes (9%$) 62.6% 
Distant – metastasized (4%$) 16.1% 
Unknown – unstaged (3%$) 78.3% 
Lifetime risk of developing melanoma& 2.1% 
Prevalence of melanoma@ 960,231 
#Age-adjusted rates based on 2007-2011 cases and deaths. §Based on 2004-2010 data. 
$Percent of all melanoma patients. &Based on 2009-1011 data. @2011 data. Adapted froma. 
 

http://www.seer.cancer.gov/statfacts/html/melan.html 
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Over the last decade in Norway, incidence rates have increased annually by 4.6% for 
men and 3.9% for women, and mortality rates have increased by 1.8% for men and 
decreased by 0.4% for womena. Five-year survival rates were 81% for men and 90% 
for women in the period 2009-2012. The recorded and predicted numbers of new 
cases and deaths per year in Norway are illustrated in Figure 8. 
 
 
Figure 8 Recorded and predicted number of annual new melanoma cases and deaths in 
Norway. Illustration by T. Sundstrøm based on incidence and mortality data from the 
Association of the Nordic Cancer Registries (NORDCAN project)b. 
 
Melanoma incidence rates have large geographical, ethnic/racial and socioeconomic 
variations258-260. These variations are tightly connected to skin type, recreational 
exposure to sunlight and indoor tanning patterns; exposure to solar ultraviolet (UV) 
radiation is the only established modifiable cause of melanoma261,262. Incidence rates 
are generally highest in white Caucasians from the more affluent parts of the world. 
Australia and New Zealand have the highest incidence rates, two to three orders of 
magnitude higher than in Norway and the US258,260. Incidence rates are two to four 
times lower in eastern European countries as compared to western European 
countries258,260. Over the last decades in the US, melanoma incidence rates have 
increased by 6.1% per year in white women younger than 44 years of age259. 
 

ahttp://www-dep.iarc.fr/NORDCAN/English/StatsFact.asp?cancer=310&country=578
bhttp://www-dep.iarc.fr/NORDCAN/English/frame.asp 
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Patients with a previous history of melanoma have an increased risk of developing 
new primary melanomas263. Other established risk factors for melanoma are 
dysplastic nevus syndrome, familial history of melanoma and certain predisposing 
genetic mutations where CDKN2A and CDK4 mutations have the highest 
penetrance264. As early identification is the most important intervention to reduce 
melanoma mortality, risk-stratified screening should be adopted to detect melanoma 
at its earliest and most curable stages264,265. 
 
4.3.3. Pediatric, uveal and amelanotic melanomas 
Pediatric melanoma is rare, but its incidence is increasing, particularly among 
adolescents266. Pediatric and adult melanomas have a very similar UV-induced 
mutational spectrum267, which emphasizes the protective role of sun protection, but 
also the potential applicability of novel therapeutics explored in adult populations. 
 
Uveal melanoma is rare, but it is the most common primary malignancy of the eye268. 
Metastatic disease occurs in up to 50% of patients, of which 90% develop liver 
metastases. Uveal melanomas frequently display activating mutations in GNAQ or 
GNA11 with subsequent MEK-extracellular signal-regulated kinase (ERK) pathway 
activation, and are possibly susceptible to MEK inhibition225 (currently under 
investigation in the trial NCT01143402). Uveal melanomas are not characterized by 
activating mutations in BRAF or NRAS269. 
 
Approximately 2-8% of melanomas are amelanotic, i.e. they lack pigmentation270. 
Amelanotic melanomas are frequently associated with diagnostic delay and have a 
higher mortality than pigmented melanomas271; brain metastasis is independent of 
pigmentation216. 
 
4.3.4. Tumor progression and staging 
Melanomas arise from skin melanocytes, either from a pre-existing nevus (20-30%) 
or with no visible precursor lesion (60-70%)272 (Fig. 9). A primary cutaneous lesion 
cannot be identified in up to 12% of patients with metastatic melanoma. 
Approximately 80% of melanocytic nevi have an activating mutation in BRAFV600E 
(Val  Glu in codon 600)273, and the constitutive activation of BRAF is thought to 
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drive the initial steps of nevus formation272. Subsequent tumor progression is driven 
by the accumulation of genetic and epigenetic events (e.g. CDKN2A mutations, PTEN 
loss). 
 
 
Figure 9 Melanoma development and progression. The tumor arises within the epidermis 
(melanoma in situ), grows into the dermis and invades lymph and blood vessels to form 
regional and distant metastases. Modified with permission from Damsky et al.272. 
 
Cutaneous melanomas are most common (91.2%), whereas acral (2.3%), mucosal 
(1.3%) and ocular/uveal melanomas (5.2) are more rare274. Different types of 
melanomas are characterized by different mutational spectra, e.g. with higher 
frequencies of BRAF mutations in areas that receive intermittent UV-exposure (e.g. 
trunk) and higher frequencies of KIT mutations in non-exposed areas (acral, 
mucosal)234. 
 
Most melanomas are diagnosed when thin (Breslow thickness ≤1 mm) and have a 
favorable prognosis with surgery alone. Nonetheless, in a study of 2,243 patients with 
thin melanomas, Maurichi et al. reported a 12-year survival of 85.3%; age, mitotic 
rate, ulceration, lymphovascular invasion, regression and sentinel node status were 
found to be independent predictors of survival275. Most recurrences occurred more 
than five years after the initial diagnosis and more than 10% developed regional or 
distant metastatic disease as the first event. 
 
Increasing Genetic Complexity
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Melanoma has a proclivity to metastasize to certain organs, primarily lung, skin, 
lymph nodes, brain and liver; however, metastases can occur anywhere and in an 
unpredictable fashion276. Superficially spreading and nodular melanomas metastasize 
more frequently to the brain, whereas acrolentiginous and mucosal melanomas more 
often spread to the skeleton277. Head and neck melanomas have a higher incidence of 
brain metastases278 and the highest incidence is seen with scalp melanomas279. 
Together, metastatic dissemination from very small tumors and widespread metastasis 
to any organ site are characteristic features of melanoma, and constitute great 
challenges for both research and clinical management. 
 
The 7th edition of the American Joint Committee on Cancer (AJCC) melanoma 
staging recommendations was published in 2009280. In brief, staging criteria include 
(T) tumor thickness, ulceration status and mitoses, (N) number of metastatic lymph 
nodes and nodal metastatic burden, and (M) site of distant metastasis and serum 
lactate dehydrogenase (LDH) status. Localized melanoma is stages I and II, regional 
metastatic melanoma is stage III, and distant metastatic melanoma is stage IV (Tab. 
6). 
 
4.3.5. Genomic landscape of melanoma 
Since the landmark publication by Davies et al. in 2002, which described a high 
frequency of BRAF mutations in melanomas232, a number of investigations have 
helped to define the genomic landscape of melanoma. The most important and 
clinically relevant alterations are summarized in Figure 10. The Cancer Genome 
Atlas (TCGA) studya on melanoma is not yet published; this study will primarily 
focus on metastatic melanoma and currently aims to collect 500 patient samples. 
 
Approximately 65% of melanomas harbor mutations in the MAPK (RAS-RAF-MEK-
ERK) pathway281-283. About 43% and 15% of melanomas have BRAF and NRAS 
mutations, respectively284. The most prevalent BRAF mutations are BRAFV600E (80%) 
and BRAFV600K (5-30%)285,286. BRAF (48%) and NRAS (15%) mutations occur with 
similar frequencies in metastatic tumors284, and mutation status is not associated with 
outcome or site of distant metastasis287,288. Concurrent NRAS and BRAFV600 mutations 

ahttp://cancergenome.nih.gov/cancersselected/melanoma 
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are rare (1.6%), whereas NRAS and BRAFNon-V600 mutations are more frequent 
(18%)289. 
 
More than 50% of melanomas have genetic alterations (CCND1, CDK4 or CDKN2A) 
that confer cyclin-dependent kinase 4 (CDK4) activation290,291. About 30% of 
melanomas have deletions or inactivating mutations in PTEN (40% of BRAF-mutant 
melanomas)291,292. Mutations or amplifications of other constituents of the PTEN-
PI3K-AKT-mammalian target of rapamycin (mTOR) pathway are infrequent293,294. 
PI3K inhibition blocks downstream signaling better than AKT inhibition295. 
Mutations or deletions in TP53, or amplifications of the cellular tumor antigen p53 
(p53) inhibitor mouse double minute 2 homolog (MDM2), are rare in melanomas296-
298. On the other hand, the p53 inhibitor protein Mdm4 (MDM4) is upregulated in 
approximately 65% of melanomas, and promotes melanoma cell survival by 
antagonizing the proapoptotic function of p53299. 
 
Next-generation sequencing studies have identified several recurrent mutations in 
melanomas, including EPHA3 and ERBB4300, MAP3K5 and MAPK3K9301, PREX2302, 
RAC1303,304, GRIN2A305, GRM3306, BAP1307, PP6C and STK19303, TERT 
promoter267,308,309 and TMEM216310. Importantly, most of these genetic alterations 
occur with relatively low frequencies (<15%; “long tail”) and few genes are validated 
across different studies. 
 
A myriad of putative mediators of metastasis have been identified, and include: 
Apolipoprotein-E (APOE)311,312, β-Catenin313, breast cancer metastasis-suppressor 1 
(BRMS1)314, CD44 splicing variant 6 (CD44v6)315, CDH13316, CDKN2A/B316, 
GRIA2311, HOXD9317, KISS-1318, liver X receptor β (LXRβ)312, MDA-9/syntenin319, 
NEDD9320, NM23321, PLEKHA5322, PRRX1323, Rho family of guanosine triphosphate 
hydrolases (GTPases) and Rho-associated protein kinase (ROCK)324,325, STAT3326, 
among others327. 
 
Several large-scale attempts have been made to identify metastasis regulators in 
melanoma by comparing messenger ribonucleic acid (mRNA) expression328-330, 
deoxyribonucleic acid (DNA) copy number changes331-333 and DNA methylation317 of 
primary and metastatic melanomas, but these analyses have shown little overlap. 
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Indeed, in a comparative analysis of 14 gene expression profiling studies, Tremante et 
al. found negligible overlap in molecular signatures between studies334. Importantly, 
melanoma is characterized by a profound and dynamic heterogeneity; in fact, 
melanoma is the most heterogeneous of all cancers335. Hence, we are faced with 
considerable obstacles in our attempts to clinically translate vast amounts of genetic 
information336 into meaningful clinical benefit for patients. Paramount in this regard 
is the development and extension of integrated platforms of accumulated knowledge 
of tumor genetics and pharmacological data337 (see Paper IV). Furthermore, to 
improve translational success rates from preclinical research, there is great need for 
more reproducible, predictive and representative animal models338,339 (see Papers I 
and II). 
 
 
Figure 10 Overview of the therapeutic biology of melanoma. The most frequent genomic 
changes in melanoma (percentages of patients with mutations or altered protein expression; 
see text for details). T lymphocytes (programmed cell death protein 1, PD-1) interact with 
melanoma cells (programmed death-ligand 1, PD-L1). Antigen-presenting cells (B7) interact 
with T lymphocytes (cytotoxic T-cell lymphocyte-associated antigen 4, CTLA-4). CCND1, 
cyclin D1; CDK4, cyclin-dependent kinase 4; CDKN2A, p16INK4A inhibitor of CDK4; 
MHC, major histocompatibility molecule; TCR, T-cell receptor. Reproduced with permission 
from McArthur and Ribas340. 
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4.3.6. Melanoma immunotherapy: past, present and future 
Melanoma is an immunogenic cancer340 with its high mutation rate and many point 
mutations335,341. Neoantigens from mutated proteins can be recognized by the immune 
system and can be exploited therapeutically to activate the immune system. Historical 
reports have indeed described an increased occurrence of melanomas in 
immunosuppressed patients342 as well as spontaneous regressions of melanoma343. 
Moreover, tumor-specific antibodies and immune infiltrates have been positively 
associated with survival344,345. 
 
Immunotherapy has been an active area of research for many years with the use of 
melanoma vaccines (e.g. inactivated tumor cells) and non-specific immune stimulants 
(e.g. Bacillus Calmette-Guerin; BCG)346. High-dose interlukin-2 (IL-2) was approved 
for the treatment of advanced melanoma in 1998, and was actually the first approved 
treatment since the introduction of dacarbizine in 1976. Although these approaches 
have failed to provide predictable clinical benefit for patients and often been 
associated with severe toxicities, there are occasional responders (usually <10% of 
patients) with profound and durable responses347,348. 
 
All immunotherapy approaches aim to induce intratumoral infiltration of activated T 
cells, which posses cancer-specific cytotoxic activity340. This also applies to adoptive 
cell transfer (ACT) with autologous T cells, which is another promising and rapidly 
evolving technology where tumor-infiltrating lymphocytes (TILs) are harvested from 
patients, expanded and activated ex vivo, and reinfused into the patient following 
chemotherapy-induced depletion of endogenous lymphocytes349. In a study of ACT 
therapy in heavily pretreated patients with metastatic melanoma, Rosenberg et al. 
reported objective cancer regression in 56% of patients350. Notably, complete 
regression was seen in 22% of patients, of which all but one patient had an ongoing 
complete response beyond three years. Indeed, TIL-based ACT is an effective therapy 
for metastatic melanoma, and represents the ultimate form of personalized medicine, 
since a new “drug” is developed for each patient349. In the future, ACT therapy can 
probably gain further momentum with simplified and automated expansion of TILs 
within the confines of blood banks or hospital laboratories. Modified ACT approaches 
and combined regimens encompassing ACT therapy are currently under investigation. 
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Immune checkpoint inhibition is the most successful immunotherapy approach to 
date346 (Fig. 10). Activation of a T lymphocyte requires (1) T-cell receptor (TCR) 
recognition of an antigenic peptide/major histocompatibility complex (MHC) on an 
antigen-presenting cell (APC), and (2) a coordinated interaction between the T 
lymphocyte and the APC through receptor-ligand immune checkpoints351. The most 
clinically relevant receptors on T lymphocytes are both inhibitory and mediate 
immune tolerance: CTLA-4 and PD-1. In 2011, the US Food and Drug 
Administration (FDA) approved the monoclonal anti-CTLA-4 antibody ipilimumab 
and, in 2014, the anti-PD-1 antibodies pembrolizumab and nivolumab. 
 
In a recent pooled analysis of long-term survival data of 1,891 ipilimumab-treated 
patients with advanced melanoma, Schadendorf et al. reported an OS of 11.4 months 
and a 22% three-year survival rate352. Survival curves plateaued around three years, 
which further substantiates the durability of ipilimumab in subgroups of patients. 
Furthermore, Maio et al. recently published long-term results of ipilimumab + 
dacarbizine in 250 patients versus placebo + dacarbizine in 252 patients with 
advanced melanoma; for patients receiving ipilimumab, the same three-year plateau 
was described and the five-year survival rate was 18.2% as compared to 8.8% for 
patients on placebo353. Pembrolizumab354, nivolumab355,356, lambrolizumab (anti-PD-1 
antibody)357 and BMS-936559 (anti-PD-L1 antibody)358 have shown even higher 
response rates and less toxicity in clinical trials than ipilimumab. Several new 
immune checkpoint blockers are in the pipeline and more regulatory approvals are 
expected in the years to come. 
 
In 2013, ipilimumab accounted for nearly 2/3 ($577 million) of total US sales of 
therapies for melanoma359. The costs and benefits associated with ipilimumab have 
been subjected to much debate360. Pre-treatment identification of patients that are 
likely to benefit from ipilimumab therapy is necessary361. Research is now focused on 
patient selection, potential synergistic effects of combinatorial regimens and 
development of novel therapies with less toxicity. Co-inhibition of CTLA-4 and PD-
1/PD-L1 is currently under investigation362. The ipilimumab + vemurafenib trial was 
stopped due to severe hepatotoxicity363, but other studies are ongoing to explore the 
potentially synergistic effects of MAPK pathway inhibition and immune checkpoint 
blockade. Conclusively, the combination of MAPK-targeted therapies with rapid 
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tumor responses and immunotherapies with durable tumor responses brings together 
the best of both worlds and holds great promise for the future. 
 
4.3.7. Current management of metastatic melanoma 
Patients with advanced melanoma should be assessed for the presence of a BRAFV600 
driver mutation, and considered for treatment with a BRAF inhibitor (vemurafenib or 
dabrafenib) and/or a MEK inhibitor (trametinib). Patients with acral or mucosal 
melanomas that are BRAFV600 negative should be examined for a KIT driver 
mutation364-368. Patients with other MAPK pathway alterations (e.g. NRAS mutation) 
often respond better to high-dose IL-2 therapy369. 
 
Phase III trials have shown a median time to tumor response with ipilimumab of 3.18 
months370 and vemurafenib of 1.45 months129. The most common (≥30%) adverse 
effects associated with vemurafenib are rash, alopecia, arthralgia, fatigue, nausea and 
photosensitivity reaction371. Keratoacanthomas and cutaneous squamous cell 
carcinomas develop in approximately 24% of patients. Ipilimumab therapy is 
typically associated with immune-related adverse events due to general 
immunological enhancement (61% total; 10-20% grade 3-4)372,373. The most clinically 
relevant immune-related immune adverse events are exanthemas, hepatic 
transaminitis and diarrhea/colitis; the latter has resulted in treatment-related deaths. 
 
The main findings from the most influential clinical trials of systemic therapies for 
patients with metastatic melanoma over the last five years are summarized in Table 7. 
These studies form the basis of our current standards of care (Fig. 11), but, notably, 
the treatment of metastatic melanoma is a rapidly transforming field with active 
preclinical and clinical research. At present, there are 423 open studies on melanoma 
at ClinicalTrials.gov (U.S. National Institutes of Health); most of these deal with 
metastatic melanoma and involve molecularly targeted therapies, immunotherapies or 
combinations thereof. 
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Figure 11 Treatment of metastatic melanoma. The possibility of clinical trial participation or 
palliative radiation therapy should be considered at all stages. (*) Ipilimumab or interleukin-2 
(IL-2): Consider ipilimumab or IL-2 for patients without brain metastases, good organ 
function, physiologic age < 70 years and normal serum level of lactate dehydrogenase (LDH). 
Consider ipilimumab alone for all other patients without autoimmune conditions. (•/Δ) 
Pembrolizumab or nivolumab: for patients with progressive disease. See also Figure 2. CNS, 
central nervous system; PS, performance status. Reproduced with permission from Kaufman 
et al.391 and UpToDatea. 
 
4.3.8. Resistance mechanisms to MAPK-targeted therapies  
Only around 50% of melanoma patients have BRAFV600 mutations, and targeted 
therapies are limited for the remaining half. Moreover, close to 10% of patients with 
mutations display primary resistance to BRAF inhibitors and progress during 
initiation of therapy387. Most responders have partial and short-lived responses, e.g. 
vemurafenib has shown a PFS of just 5.3-7.3 months129,246,374,376,379,381. Furthermore, 
gains in OS are modest; vemurafenib trials have shown an OS of 12-17.2 
months246,374,376,379 as compared to 9.1-10.5 months in contemporary dacarbizine 

ahttp://www.uptodate.com 
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series373,375,379. Most of the published trials of MAPK-targeted therapies (Tab. 7) 
show similar limitations in therapeutic efficacy and durability, and suggest that there 
are both intrinsic and adaptive mechanisms that need to be overcome (see Paper IV). 
 
Acquired drug resistance is a major issue with the new MAPK-targeted therapies and 
resistance mechanisms usually involve reactivation of the MAPK pathway392-395 (Fig. 
12). Recent insights have been achieved through a wide-range of preclinical 
investigations using drug-resistant BRAFV600E-mutated cell lines. 
 
 
Figure 12 Mechanisms of acquired 
resistance to BRAF inhibitor therapy. 
MAPK-reactivating mechanisms (left) 
and distribution of core pathways among 
progressive melanomas (right). Adapted 
and reproduced with permission from Shi 
et al.393. 
 
Mechanisms of resistance to MAPK-targeted therapies: 
(1) ERK activation can be restored through several bypass mechanisms within the 
MAPK pathway regardless of ongoing BRAF inhibition: activating mutations in 
NRAS394,396,397 or MEK138,394,398, upregulation of RAF proto-oncogene 
serine/threonine-protein kinase (CRAF)399,400, activation of serine/threonine 
kinase Cot (COT)/MAP3K8399, overexpression of mutant BRAF401, upregulation 
of platelet-derived growth factor β (PDGFRβ)396 or receptor tyrosine-protein 
kinase erbB-2 (ERBB2)399, and inactivation of neurofibromin (NF1)402. 
(2) Modified forms (splicing variants) of the BRAF protein that are insensitive to 
BRAF inhibitors have been found in a significant subset of patients with 
acquired resistance403. 
(3) Compensatory activation of the PI3K-AKT pathway can sustain cell growth and 
survival through adaptive upregulation (e.g. increased expression of insulin-like 
growth factor 1 receptor (IGF-1R))404 and activating mutations (e.g. AKT1 
Q79K mutant)405. 
(4) Intrinsic406 or acquired407 induction of the microphthalmia-associated 
transcription factor (MITF) and the mitochondrial master regulator peroxisome 
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proliferator-activated receptor γ coactivator 1-α (PGC1α) result in enhanced 
mitochondrial oxidative phosphorylation (OXPHOS) and reactive oxygen 
species (ROS) detoxification capacities. Melanoma cells become addicted to 
mitochondrial respiration and show resistance to BRAF inhibitors (see Paper 
IV). 
(5) Increased CDK4 activity due to elevated levels of CRAF400, CCND1 (cyclin 
D1) amplification408,409, activating mutations in CDK4409 or loss of its inhibitor 
p16INK4A inhibitor of CDK4 (CDKN2A)408 increases cell proliferation, and 
may both confer baseline and acquired resistance to MAPK-targeted therapies. 
(6) Increased expression of the antiapoptotic Bcl-2-related protein A1 
(BCL2A1)410, elevated levels of the hepatocyte growth factor (HGF)411,412 or 
loss of the tumor suppressor PTEN408 may confer intrinsic resistance to BRAF 
inhibitors. 
 
4.3.9. Challenges and future directions of melanoma therapy 
Contemporary therapy for metastatic melanoma is hampered by limited efficacy and 
durability, partly due to intrinsic and adaptive resistance mechanisms413,414. Moreover, 
there are significant concerns with regards to drug-related adverse effects233,234, 
patient selection criteria225,361 and cost-benefit359,360. Most importantly, melanoma is 
characterized by a high genomic complexity and variability, and a high metastatic 
potential. This section will focus on molecularly targeted therapies. Future directions 
of immunotherapy are outlined above (section 4.3.6.). 
 
Preclinical investigations suggest that discontinuous dosing schedules might forestall 
BRAF inhibitor resistance and sustain drug sensitivity415. Recent clinical trials 
indicate that newly diagnosed BRAF-mutated patients benefit from combined BRAF + 
MEK inhibition as opposed to BRAF or MEK monotherapy376,377,380,381,385 (Tab. 7). 
Preclinical evidence suggests that the ERK inhibitor SCH772984 can overcome 
acquired resistance to BRAF and MEK inhibitors416. Clinical trials of ERK inhibitors 
are currently ongoing, but information thus far is scarce. Efficient ERK 
phosphorylation is dependent of the interaction between copper and MEK1, and 
recent work has found copper chelation therapy to decrease proliferation of naïve and 
drug resistant human and murine BRAFV600E-mutated melanoma cells417. Many 
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components of the MAPK pathway are reliant on the chaperone protein heat shock 
protein 90 (HSP90), including BRAF, CRAF and COT proteins, and preclinical work 
have demonstrated that HSP90 inhibitors can abrogate BRAF inhibitor resistance418; a 
clinical trial combining vemurafenib and the HSP90 inhibitor XL888 is currently 
ongoing (NCT01657591). 
 
Combinations of BRAF-MEK-ERK pathway inhibitors and PI3K-AKT-mTOR 
pathway inhibitors could prevent therapeutic escape through enhanced PI3K-AKT-
mTOR signaling393,404,419. This combination will probably have a narrow therapeutic 
window as both pathways are implicated in multiple cellular processes340,414; 
nevertheless, several clinical trials are underway (e.g. NCT01616199, 
NCT01519427). 
 
Direct targeting of the neuroblastoma RAS viral oncogene homolog (NRAS) has 
proven to be difficult, but combination therapies that block downstream signaling may 
provide benefit to NRAS-mutated patients (e.g. BRAF, ERK)420. In a recent meta-
analysis of somatic mutations from next generation sequencing of 241 melanomas, 69 
tumors were found to be BRAFWT, NRASWT and KITWT (“pan-negative”) and 12 
potential driver mutations were identified (ADAMTS18, ALK, DGKI, EPHA4, 
EPHA7, ERBB4, KDR, NF1, RAC1, STK31, SYK and TAF1L), each in a small 
percentage of patients421. Strategies to target these “pan-negative” melanomas have 
proven even more elusive than NRAS-mutant melanomas413. 
 
Early treatment responses should be evaluated so that combination therapies can be 
personalized or modified before resistance ensues413. For this, better biomarkers are 
needed; proteomic methods and analyses of circulating tumor cells/DNA are currently 
being explored.  
 
The majority of actionable driver mutations in melanoma have probably been 
identified and a vast amount of knowledge has been generated about the molecular 
biology of melanoma336. Still, we have a limited grasp of the complexity of this 
intricate genomic network337 as well as the associated intra- and intertumoral 
heterogeneity303,335. As our knowledge evolves, significant improvements should be 
expected in both durability and efficacy of targeted therapies (see also section 4.3.5.). 
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There is also a prevailing need for novel drugs with more broad-spectrum efficacy 
against metastatic melanoma, including drugs that can prevent the emergence of 
metastatic disease5,17,312,414,422-425. A rapidly evolving field of research involves 
decoding and therapeutic interference of the rewired metabolic network in cancers, 
including melanomas426,427. This is further discussed in Papers III and IV, and in 
section 4.4.2.6. 
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4.4. MELANOMA BRAIN METASTASIS 
 
4.4.1. Contemporary clinical and preclinical landscape 
Melanoma is the fifth most common cancera, but the third most common cause of 
brain metastases3,6,18,32. Hence, melanoma patients carry a high risk of developing 
brain metastases5,428-430. Recent advances in systemic therapies for metastatic 
melanoma offer promise (Tab. 7), but have thus far provided limited benefit for 
patients with brain metastases (Tab. 4; section 4.2.3.4.3). 
 
Melanomas are characterized by a high metastatic capacity431 and unprecedented 
genetic heterogeneity303,335. Brain metastases find protection and alliance beyond the 
BBB/BTB and within the brain microenvironment5,44,432. These features require robust 
and representative preclinical model systems (see Papers I and II) to elucidate the 
biology and assess new therapies in preventive and established scenarios (see Papers 
III and IV). 
 
4.4.2. Biology of melanoma brain metastasis 
Pioneering studies from Isaiah Fidler and others have provided important insights into 
the molecular biology of melanoma brain metastasis429. However, the regulatory 
mechanisms are still relatively poorly understood and knowledge is fragmented272. 
The causal mechanisms of brain-specific tropism, increased BBB permeability and 
enhanced cell survival in the brain are not fully characterized or understood. A myriad 
of proposed mechanisms underscore the complexity of this process, and reflect the 
profound and dynamic intra- and intertumoral heterogeneity of melanomas. A better 
and more integrated understanding of the molecular biology is critical to the 
development of new preventatives and therapeutics. 
 
4.4.2.1. Animal models 
Animal models involving hematogenous dissemination of cancer cells have been 
important tools of brain metastasis research for many years, despite their inherent 
methodological flaws433-437. The values and limitations of past and present pan-cancer 
animal models of brain metastasis are reviewed in Paper I. In brief, we can apply the 

ahttp://www.seer.cancer.gov/statfacts/html/melan.html 
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well-worn dictum “all models are wrong, some models are useful”438. A further 
discussion of reproducibility and predictivity of brain metastasis models is provided 
in Paper II and animal models are employed in Papers II-IV. 
 
4.4.2.2. Preclinical imaging 
MRI, PET and bioluminescence imaging (BLI) are complementary, noninvasive 
imaging platforms that enable exceptional temporal and spatial tracking of multiple 
tumors in a single mouse439. This is clearly advantageous for metastasis models, 
which typically involve many tumors. Not only can we follow the total tumor burden 
over time, we can also visualize and differentiate tissue specific effects, and evaluate 
both growth inhibition and targeting efficacy. MRI is the best modality for brain 
imaging due to its high spatial resolution and excellent tissue contrast, whereas PET 
and BLI provide high sensitivity and overview of systemic tumor involvement439. 
PET imaging suffers from limited availability and throughput, but is rapidly evolving, 
both in the preclinical and clinical setting440,441. 
 
MRI alone cannot identify single tumor cells or micrometastases in the brain. 
Nanoparticle-based contrast agents for MRI have thus seen an increasing use in 
preclinical research, clinical diagnostics and therapeutics439. Superparamagnetic iron 
oxide nanoparticles (SPIONs) have dominated the field of MRI-based cell 
tracking439,442. MRI coupled with cellular SPION labeling provides the opportunity to 
visualize and quantify cancer cells and tumors in the brain. Utilities and caveats of 
SPION labeling in brain metastasis models are specifically discussed in Paper II. The 
value of multimodal imaging is discussed in Paper I and its applied in Papers II-IV 
to facilitate reproducible and predictive in vivo modeling of melanoma brain 
metastasis. 
 
Early detection of brain metastases is critical and several techniques are currently in 
preclinical development. These include a method that specifically permeabilize the 
BBB at sites of brain metastases using recombinant human tumor necrosis factor 
(TNF) and that enables detection of micrometastases not visible using standard 
imaging modalities443. Another promising technique utilizes a targeted MRI contrast 
agent where microparticles of iron oxide are conjugated to antibodies against vascular 
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cell adhesion molecule-1 (VCAM-1). These complexes may be detected when they 
bind to the endothelium of developing tumor-associated blood vessels444. At clinical 
imaging resolutions, this technique could translate to metastasis detection at volumes 
two to three orders of magnitude smaller than currently possible (0.3-3 × 105 cells 
versus 107-108 cells). 
 
4.4.2.3. The metastatic process: seed, soil and climate 
In 1889, Stephen Paget presented the “seed-and-soil” theory where he suggested that 
inherent qualities of different seeds (=tumor cells) make them more prone to grow in 
different soils (=organ microenvironments)445. This organ specificity of various 
cancers has been experimentally confirmed in numerous studies, including 
melanomas446-448. It seems the metastatic pattern of melanomas is not explained by the 
anatomy of circulation alone; however, head and neck melanomas do have a higher 
incidence of brain metastases278,279. Evidence also suggests that the “climate” (=the 
host) is an important determinant of tumor growth in distant organs449; Chen et al. 
showed that the same cancer cell line could be bone-tropic in one mouse strain and 
liver-tropic in another host strain450. 
 
There is no lymphatic system in the brain. Circulating tumor cells are lodged in the 
brain microvasculature and traverse the BBB to form brain metastases (Fig. 13). 
These unique steps of tumor formation from the single-cell level have been elegantly 
characterized by real-time imaging with multiphoton laser scanning microscopy in 
mice451. In this study, Kienast et al. also demonstrated the inefficiency of the 
metastatic process as well as the presence of long-term dormancy. Following capillary 
arrest, some tumor cells adhere to the vessel endothelium and extravasate into the 
brain parenchyma, a process dependent on close interaction with the vascular 
basement membrane451-453. Melanoma cells that later give rise to brain metastases 
extravasate within 3-7 days after inoculation441,451. Melanoma cells remain in close 
contact with microvessels and co-opt these for nutrients, as opposed to lung cancer 
cells who induce neoangiogenesis. Correspondingly, Kienast et al. showed that 
VEGF-A inhibition induced co-option and prevented tumor formation in lung cancer 
brain metastases, whereas melanoma brain metastasis was not influenced by VEGF-A 
inhibition451. 
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Figure 13 Homing and colonization of cancer cells to a distant organ. Circulating tumor cells 
can become lodged in the capillary bed of distant organs. Organ-specificity may be dependent 
of site-specific adhesion, chemoattractants or seeding to pre-metastatic niches (i.e. fertilized 
microenvironments). Cancer cells that extravasate may remain quiescent (dormant) or step-
wise evolve into a metastatic tumor, processes that rely on stimulatory/inhibitory interactions 
with the organ environment and recruitment of adequate blood supply. Successful 
colonization requires stem-like properties (e.g. enhanced tumorigenicity, self-renewal 
potential). Mechanisms governing brain-specific homing and colonization of melanomas are 
discussed in the text. From Chaffer et al.2. Reprinted with permission from the American 
Association for the Advancement of Science (AAAS). 
 
4.4.2.4. The blood-brain barrier 
The BBB protects the brain from endogenous and exogenous toxins. Capillary 
endothelial cells in the brain lack fenestrations, have low pinocytosis, high electrical 
resistance, are inter-connected by tight junctions and express high levels of drug 
efflux transporters. Moreover, a basal membrane, extracellular matrix, astrocytic end-
feet and pericytes surround the outer surface of brain endothelial cells. All these 
factors comprise the BBB, which limit the penetration of drugs into the brain. 
 
Drugs that effectively traverse the BBB by means of passive diffusion have low 
molecular weights (<400 Da) and they are nonpolar and lipophilic454,455. Hydrophilic, 
polar and large molecules are reliant of active transport systems. There is major 
research activity in the reengineering of drugs to access carrier-mediated or receptor-
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mediated transport systems within the BBB455, and in the development of strategies to 
circumvent the BBB44. 
 
The BBB around tumors – the BTB – is often compromised456, but the BTB is still a 
significant obstacle to drug delivery and efficacy. In an analysis of more than 2,000 
experimental brain metastases from breast cancer, Lockman et al. reported a higher 
uptake of chemotherapeutic agents in metastases than in normal brain457. However, 
there was less than 15% uptake in brain metastases compared to that of extracranial 
tissues/metastases, and cytotoxic concentrations were only achieved in about 10% of 
brain metastases. 
 
4.4.2.5. Molecular biology 
Paper I features a short review of the molecular determinants of brain metastasis 
across different cancers, including melanomas. Importantly, although several genes 
and proteins have been found selectively expressed in brain-metastatic cells, there is 
little overlap between studies, models and cancers. In the following, I will elaborate 
on some of the molecular factors that are specifically important in melanoma and/or 
reported to be specifically associated with melanoma brain metastasis in the literature.
Metabolic pathways in melanoma brain metastasis are discussed in the next section. 
 
MAPK pathway 
Molecular profiling of matched brain and extracranial metastases of melanoma 
recently revealed full concordance for 156 known hotspot mutations (including driver 
mutations in BRAF and NRAS) as well as similar overall patterns of copy number 
variations, mRNA expression and protein expression458. Hamilton et al.’s study of 
matched extracranial metastases and brain metastases confirmed this similarity in 
gene expression profiles; there were no significantly enriched pathways between the 
two groups328. Niessner et al.’s study of matched extracranial metastases and brain 
metastases found no differences in BRAF or NRAS mutation status and identical ERK 
and pERK immunohistochemical staining patterns459. Capper et al. found no 
relationship between BRAFV600E status and survival in matched primary metastases 
and brain metastases from melanoma patients, but BRAFV600E-positive patients were 
younger than BRAFV600E-negative patients460. 
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PTEN-PI3K-AKT pathway 
Overexpression of AKT enhances the invasiveness and growth of primary melanomas 
through increased VEGF expression, ROS production and switch to a glycolytic 
phenotype461. Analyses of human melanoma metastases and human melanoma cell 
lines have shown higher levels of phosphorylated AKT and lower PTEN protein 
levels in BRAF-mutant melanomas compared to NRAS-mutant melanomas, and in 
melanoma brain metastases compared to lung and liver metastases462. However, the 
levels of AKT or PTEN did not predict survival. In contrast, Bucheit et al. recently 
showed that PTEN loss in melanoma lymph node metastases correlated with 
decreased OS and shorter time to brain metastasis. Studies of matched melanoma 
brain metastases and extracranial metastases have confirmed increased PI3K-AKT 
activation and PTEN loss in brain metastases458,459. Inhibition of PI3K-AKT signaling 
has been proposed to enhance and/or prolong the effects of BRAF inhibitors in 
patients with melanoma brain metastases459; PI3K inhibition blocks downstream 
signaling better than AKT inhibition295. 
 
JAK-STAT pathway 
The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) 
pathway promotes survival, growth and angiogenesis. Experimental studies have 
shown that STAT3 activation via phosphorylation326 or downregulation of its inhibitor 
suppressor of cytokine signaling 1 (SOCS-1)464 increase the expression of matrix 
metalloproteinase-2 (MMP-2), basic fibroblast growth factor (bFGF) and VEGF with 
consequent melanoma invasion and angiogenesis. Silencing of the immunoregulatory 
protein B7 homolog 3 (B7-H3) has been found to decrease STAT3 and 
metalloproteinase activation, and reduce melanoma brain metastasis in vivo465. Yet, 
STAT3 activation is generally associated with a pro-metastatic phenotype, and might 
not be a brain-specific phenomenon466. 
 
Migration/Adhesion 
Cellular adhesion molecules like VCAM-1 have been shown to play important roles 
in the early steps of breast cancer brain metastasis444,467. Melanoma-bearing mice with 
negligible levels of stimulatory cytokines (tumor necrosis factor alpha (TNFα) and 
interleukin-1β (IL-1β)) also display upregulated endothelial expression of VCAM-1 in 
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the brain, suggesting a direct interaction between tumor cells and the endothelium468. 
Interestingly, VCAM-1 gene expression was found to be positively associated with 
survival in metastatic melanomas along with a cluster of immune response-related 
genes, indicating a benefit of an existent immune presence in melanomas469. 
Prolonged patient survival in patients with melanoma brain metastases was also 
associated with tumor immune infiltrates and several immune-related gene sets in a 
study of matched primary melanomas, extracranial and brain metastases328. 
 
Chemokine receptor/ligand interactions might be involved in organ-specific 
metastasis of melanoma through regulation of chemoattraction, adhesion and 
survival470. The C-C chemokine receptor type 4 (CCR4) has been found 
overexpressed in a melanoma brain metastasis cell line compared to its corresponding 
cutaneous variant471. Brain-derived soluble factors have been shown to upregulate 
CCR4 in matched cutaneous and brain-metastatic cells, but only brain-metastatic cells 
displayed increased migration472. This divergent ability to respond to motility-
enhancing signals (e.g. chemokine (C-C motif) ligand 22 (CC22)) could be explained 
by either an acquired ability in the brain or an inherent ability that attracted these cells 
to the brain in the first place. The C-X-C chemokine receptor type 4 (CXCR4)/stromal 
cell-derived factor 1α (SDF-1α) receptor/ligand interaction has been shown to 
facilitate directed migration of breast cancer cells through human brain microvascular 
endothelial cells473. 
 
Melanoma cells and platelets interact with endothelial selectins in the brain 
microvasculature to facilitate adhesion to the vessel wall474. Preclinical studies 
suggest that heparin in clinically relevant doses can inhibit adhesion and attenuate 
melanoma brain metastasis formation. 
 
Invasion/Colonization 
Both melanoma cells and their conditioned media have been found to compromise 
junctional integrity by reducing transendothelial electrical resistance and disrupt tight 
junction molecules like claudin-5 and tight junction protein ZO-1 (ZO-1)475. This 
process is incompletely understood, but proteolytic enzymes are probably involved. 
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Melanoma cells colonize the brain while in close contact with the vasculature451,452, 
and might utilize connexin gap junction proteins to initiate tumor formation within the 
vascular niche476. Connexin 26 was shown to mediate extravasation and vessel co-
option using transparent zebrafish and chicken embryo models of melanoma brain 
metastasis476. Other studies have shown that activated astrocytes protect brain-
metastatic melanoma cells from chemotherapeutic drugs, and this effect was 
dependent on physical contact and gap junctional communication between tumor cells 
and astrocytes477. Whether this chemoprotection could be abrogated by connexin 
inhibition remains to be determined. 
 
Endothelin receptor B (EDNRB) overexpression induced overall metastasis and brain 
metastasis in a spontaneous brain metastasis model of melanoma478. The interaction 
between EDNRB and its endothelin ligands, which are highly expressed in the brain 
relative to other organs, was proposed to mediate the increased incidence of brain 
metastases and promote intracranial tumor growth. Previous work has also implicated 
EDNRB in melanoma progression and shown that EDNRB activation mediates cell 
proliferation, adhesion, migration and matrix metalloproteinase-dependent 
invasion479. EDNRB might be facilitator of metastatic spread in general, but 
particularly important in the brain where its ligands (especially endothelin-3 (ET3)) 
are abundant478. 
 
Heparanase (HPSE) cleaves heparin sulfate chains of proteoglycans in the 
extracellular matrix and has been linked to tumor growth, invasion and angiogenesis. 
Elevated levels of HPSE have been shown to augment invasion of brain-metastatic 
melanoma cells in a brain slice model480. Co-incubation of astrocytes with brain-
metastatic melanoma cells further increased HPSE activity and invasion in vitro481. 
Neurotrophins and neurotrophin receptors have been proposed to mediate brain-
specificity in melanoma metastasis through ligand/receptor interactions like nerve 
growth factor (NGF)/p75 neurotrophin receptor and neurotrophin-3 (NT-
3)/ropomyosin receptor kinase C (TrkC), but also to promote brain colonization 
through enhanced HPSE production482. Moreover, microRNA (miR)-1258 has been 
found to suppress breast cancer brain metastasis in vivo through direct targeting of 
HPSE483. Both active and latent forms of HPSE can modulate the invasive phenotype 
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driven by GTPases such as Ras-related C3 botulinum toxin substrate 1 (Rac1) and 
Ras homolog gene family, member A (RhoA) in brain-metastatic melanoma cells484. 
 
Overexpression of the antiapoptotic protein BCL2A1 in melanomas did not increase 
brain metastasis in a spontaneous brain metastasis model, but appeared to facilitate 
tumor growth in an orthotopic model478. BCL2A1 has also been associated with 
intrinsic resistance to BRAF inhibitors410. 
 
The transforming growth factor-β (TGF-β) cytokine family is involved in a range of 
biologic processes. TGF-β2 has been found to be a molecular determinant of 
parenchymal brain metastases, but not meningeal or ventricular metastases485. TGF-
β2 has also been shown to promote the growth of GBMs486; suggesting that there are 
common microenvironmental factors that might facilitate tumor progression in 
specific organs. Moreover, TGF-β signaling has been implicated in acquired BRAF 
and MEK inhibitor resistance via induction of EGFR and PDGFRβ expression487. 
 
Melanotransferrin, a surface antigen of melanoma cells, has been found to stimulate 
plasmin formation and subsequent invasion via cleavage of extracellular matrix 
proteins and growth factor precursors. Inhibition of melanotransferrin reduced the 
ability of melanoma cells to cross the BBB and form brain metastases in mice488. 
Direct plasmin inhibition has also resulted in reduced brain metastasis in mouse 
models of melanoma489. Moreover, tumor-expressed inhibitors of plasminogen 
activator (PA), serpins, have been found to inhibit melanoma lung metastasis490. Joan 
Massagué’s group recently described a different mechanism491. They found that 
metastasis-associated astrocytes released PA in the presence of extravasated breast 
and lung cancer cells. Plasmin subsequently stimulated FasL-mediated apoptosis of 
cancer cells and inhibited L1 cell adhesion molecule (L1CAM)-mediated vascular co-
option. Brain-metastatic cells could block these effects by releasing anti-PA serpins 
and thus promote cell survival and growth. Thus, plasmin might have both pro- and 
anti-metastatic effects in the brain and the role of serpins in melanoma brain 
metastasis is unclear. 
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MicroRNAs 
MicroRNAs (miRNAs) are small noncoding RNAs that negatively regulate gene 
expression at the post-transcriptional level, and have been implicated in brain 
metastasis from several cancers492. Co-culture with astrocytes downregulated miR-
768-3p in brain-metastatic melanoma cells; miR-768-3p drives KRAS expression and 
the downstream effectors ERK and BRAF493. Exosomes of matched breast cancer and 
melanoma brain metastases and their primary tumors showed upregulated miR-210 
and downregulated miR-19a and miR-29c, which are implicated in adhesion and 
invasion494. Overexpression of miR-146a suppressed migratory and invasive capacity 
in brain-metastatic melanoma cells via upregulation of β-Catenin and downregulation 
of matrix metalloproteinases495. MiR-1258 was discussed above483. Given the ability 
of miRNAs to control multiple targets, they are promising candidates to regulate such 
a complex process as metastasis. 
 
4.4.2.6. Metabolic pathways 
In recent years, it has been shown that several genetic and molecular drivers of 
melanoma modulate cellular metabolism in ways that are critical to tumor 
development, metastasis and drug resistance (reviewed in426,427). Little is known about 
the metabolic rearrangements in melanoma brain metastases, but in breast cancer it 
has been found that metastatic cells adapt their energy production to facilitate growth 
and survival in the brain496,497. Breast cancer cells in the brain can for example 
proliferate independent of glucose496 and have been shown to utilize mitochondrial 
respiration for energy production and antioxidant defense497. Whether these changes 
reflect intrinsic or adaptive properties of tumor cells to thrive in the neural niche 
remains to be determined. However, brain-metastatic cells from breast cancer have 
been found to display neuron-like characteristics in the brain 
microenvironment311,498,499. Moreover, the brain interstitium is a low glucose 
environment496, and when cancer cells are deprived of glucose they switch from 
glycolysis to OXPHOS500. Melanomas display significant intra- and intertumoral 
heterogeneity in their expression of genetic drivers303,335 and in mitochondrial versus 
glycolytic function501-503. Still, cell lines derived from metastatic melanomas and 
melanoma metastases (none from brain) have revealed elevated levels of OXPHOS 
compared to primary melanomas503,504. The balance between glycolysis and OXPHOS 
 75 
is probably skewed towards glycolysis in the hypoxic tumor core and towards 
OXPHOS in the oxygenated tumor periphery of metastatic melanomas. The former 
might be mediated by increased hypoxia-inducible factor 1α (HIF1α)-dependent 
expression of LDHA and conversion of pyruvate to lactate504,505. Hence, the 
contribution of the Warburg effect506,507 – aerobic glycolysis instead of OXPHOS in 
cancer cells and consequent lactate production – can be different in metastatic and 
primary melanomas, and in different organ microenvironments. 
 
The spatial, temporal and functional features of LDHA in melanoma brain metastasis 
are discussed in Paper III. Inhibition of mitochondrial respiration is discussed in 
Paper IV. 
 
The MAPK pathway is a key regulator of metabolism in melanomas426,427 (Fig. 14). 
Signaling through the MAPK pathway increases glycolytic activity508 and reduces 
mitochondrial respiration406,407,509. BRAF inhibitors confer the opposite 
effect406,407,508,510,511. One of the mediators of MAPK signaling is pyruvate 
dehydrogenase kinase, isoenzyme 1 (PDK1), which inhibits pyruvate dehydrogenase 
(PDH)-mediated entry of acetyl-CoA into the citric acid (TCA) cycle509. PDK1 is 
suppressed in BRAF-mutated melanomas, and treatment with BRAF inhibitors 
restores PDK1 activity. PDK1 inhibitors (e.g. dichroacetate) have been found to 
synergize with BRAF inhibitors and abrogate BRAF inhibitor resistance508,509. The 
MITF-PGC1α axis is another important regulator of mitochondrial activity in 
melanomas, and induction of MITF and PGC1α increases OXPHOS and ROS 
scavenging capabilities406,407. A subset of melanomas overexpresses PGC1α406, and 
treatment of BRAF-mutated melanomas with BRAF inhibitors upregulates PGC1α407; 
both of these groups display increased OXPHOS and ROS detoxification capacities. 
Notably, these mechanisms can provide intrinsic and acquired survival advantages, 
but the resultant dependence of OXPHOS also opens up the possibility of targeting 
OXPHOS in melanomas406,407,510,511. 
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Figure 14 Regulatory network of cell signaling, transcription and metabolism in melanoma. 
Growth factor-mediated activation of receptor tyrosine kinases (RTKs) leads to downstream 
activation of the RAS-RAF-MEK-MAPK and PI3K-AKT-mTOR pathways. MAPK suppresses 
LKB1/AMPK energy sensing and AKT triggers increased glucose import via the glucose 
transporter GLUT4. MAPK stabilizes and mTOR increases translation of HIF1α. Increased 
HIF1α activity (1) decreases MITF and PGC1α levels and subsequent mitochondrial bioactivity, 
and (2) increases PDK1 activity, which in turn inhibits PDH-mediated entry of acetyl-CoA into 
the TCA cycle. The combined result of these regulatory interactions is increased glycolysis and 
decreased mitochondrial respiration. Frequently mutated components in human cancers are 
indicated in red and known inhibitors are indicated in blue. See text for more details. 
Reproduced with permission from Haq et al.427. 
 
Corazao-Rozas et al. found in vitro and in vivo support of adding elesclomol, which 
targets the mitochondrial electron transport chain, to vemurafenib-resistant 
melanomas510. The antidiabetic biguanides metformin and phenformin inhibit 
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mitochondrial Complex I (CI), and increase AMPK-dependent mTOR inhibition426. 
Niehr et al. found synergistic effects in vitro of vemurafenib and metformin in BRAF- 
and NRAS-mutated melanomas512. It has been argued that the effective dose levels of 
metformin in vitro were too high to be clinically relevant426,513, but observations also 
suggest that metformin accumulate in target organs in vivo and in humans to 
concentrations that are much higher than plasma concentrations514. Yuan et al. found 
enhanced therapeutic benefit of BRAFV600E inhibition in melanoma xenografts with 
the more potent biguanide phenformin513. These studies suggest a therapeutic 
potential for mitochondrial inhibition, but further studies are needed to determine the 
clinical utility of these findings. 
 
Many metabolic modulators like natural compounds and drugs used for other 
conditions than cancer have favorable cost and toxicity profiles, and might offer 
additional therapeutic benefit in metastatic melanoma. The abovementioned 
importance of mitochondrial respiration in melanoma brain metastases might suggest 
even greater advantage of mitochondrial inhibition in preventing and treating brain-
metastatic lesions (see Paper IV). 
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5. AIMS 
 
The overall aim of this thesis was to study the biology of melanoma brain metastasis 
and find novel therapeutic strategies in vivo. 
 
The main aims of each study were: 
 
Paper I 
To review the current literature on animal models of brain metastasis and critically 
address their pros and cons. 
 
Paper II 
To develop a reproducible and predictive mouse model of melanoma brain metastasis. 
 
Paper III 
To examine the mechanistic importance of LDHA in melanoma brain metastasis in 
vivo. 
 
Paper IV 
To identify potential therapeutic compounds against melanoma brain metastases 
based on genomics-based drug repositioning and functional assessment in vivo. 
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6. DISCUSSION 
 
Papers I-IV are cited in relevant sections throughout the general introduction. Here, I 
will discuss the timeliness, key results and methodological considerations of each 
study. 
 
6.1. Paper I 
We reviewed the literature on the various animal models used to study brain 
metastasis, and sought to attain an overview of their strengths and weaknesses. Our 
review was placed in the context of the multi-step metastatic process and the limited 
overlap of molecular signatures between studies (Fig. 15). Taken together, models are 
just models, and none of them fully reflect the complexity or biology of brain 
metastasis. Thus, experimental findings should be interpreted with caution, examined 
across different models and human validation is essential. 
 
 
Figure 15 Genes implicated in brain metastasis. These genes are derived from preclinical and 
clinical studies, and the missing overlap between different models is evident. However, there 
is also significant discordance within model systems. For further details of molecular and 
genetic mechanisms, see previous sections on melanoma and melanoma brain metastasis and 
reviews5,17,44,429. GEMMs, genetically engineered mouse models. Reproduced with permission 
from Daphu et al.515. 
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Many different models are available, but mouse or rat models are mostly used. These 
models typically rely on inoculation of cancer cell lines from rodents into rodents 
(syngeneic), or inoculation of cancer cell lines or tissues from humans into rodents 
(xenogeneic). The inoculation route is orthotopic (into the organ of origin) or ectopic 
(into another organ/site). Genetically engineered mouse models (GEMMs) are 
genetically modified by for example insertion of an oncogene or deletion of a tumor 
suppressor gene, and have so far had limited impact in brain metastasis research. 
Human-to-rodent xenograft models rely on the use of immuno-compromised hosts, 
whereas syngeneic models and GEMMs enable study of the interaction between 
immuno-competent hosts and tumor cells. 
 
Some of the most valuable, available and least expensive animal models for brain 
metastasis research are those using human tumor xenografts and immunodeficient 
mice436 (see Paper II). However, they are also some of the most criticized models516. 
Moreover, data from cancer cell lines grown in vitro and in vivo should be cautiously 
evaluated. Gillet et al. found established cell lines from six different cancers to be 
genetically more similar to each other than to the clinical samples they were supposed 
to model517. Domcke et al. compared the genetic similarity between 47 cancer cell 
lines and 316 tumor samples; the commonly used cell lines were most different and 
the least used cell lines were most similar to the tumors518. Integration with human 
tissue biobanks and clinical outcome data add clinical relevance to these model 
systems519, and cellular characterization and authentication is instrumental in model 
development (see previous work from our group520,521 and Papers II-IV). 
Conclusively, standardized and reproducible animal models are needed to uncover the 
biology of melanoma brain metastasis and to improve clinical translation (see Paper 
II). 
 
I would like to draw attention to two important, but different, animal models of 
melanoma brain metastasis. First is the model by Kienast et al. using multiphoton 
laser scanning microscopy through cranial windows to image the single steps of 
metastasis formation451. This model allows high-resolution, real-time tracking of 
cancer cells in relation to blood vessels within the live brain over months, and enables 
the observation of metastasis as a process rather than a simple endpoint (see also 
section 4.4.2.3.). Second is the model by Cruz-Munoz et al., which is a unique 
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orthotopic human melanoma xenograft model with spontaneous brain metastasis522. In 
contrast to models based on intracardiac or intracarotid injections (commonly referred 
to as experimental models), this model enables examination of all steps in the 
metastatic cascade and closely resembles clinical disease. However, metastases 
develop slowly and appear in only approximately 50% of mice; hence, therapeutic 
experiments might be laborious and require large numbers of mice523. Using this 
model system, Cruz-Munoz et al. identified the significance of EDNRB and BCL2A1 
in promoting melanoma brain metastasis478 (see also section 4.4.3.5.). 
 
6.2. Paper II 
We here report on the development and validation of a novel and reproducible brain 
metastasis model that routinely incorporates automated quantification of nanoparticle-
labeled melanoma cells in the brain. We show that brain metastasis formation is 
dependent on the brain cell load, recapitulates the spread and growth seen in humans 
and is unaffected by nanoparticle labeling. This model enables early homogenization 
of study animals. This is essential to draw reliable conclusions of biologic differences 
and therapeutic efficacy (Fig. 16), and the model can readily be tailored to other 
cancer cell lines. We propose that it can help increase the poor success rates of anti-
cancer agents in clinical trials, which currently display 95% drug attrition rates524. 
 
This project was inspired by the difficulties associated with intracardiac injections in 
mice, which is one of the most used techniques to study brain metastasis. We were 
also motivated by the heterogenous metastatic potential of cancers and the 
inefficiency of the metastatic process. Not surprisingly, we found the tumor cell load 
in the brain at baseline to be strongly correlated to the formation of brain metastases. 
Importantly, MRI-based quantification of SPION-labeled cells was superior to 
standard BLI methods in evaluating injection success or failure. Not only could we 
discriminate hits and misses with more certainty than BLI, but everything in between, 
and importantly, we showed that this is related to metastasis formation. Following this 
publication, we have extended our model to include US-guidance using a custom-
made needle-holder (see Papers III and IV). US-guided intracardiac injection does 
improve reproducibility, but it does not make MRI-based quantification superfluous. 
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Figure 16 Quantification of SPION-labeled melanoma cells improves the predictive power of 
an experimental brain metastasis model. (A) Mice in groups A and B are injected 
intracardially at time zero. T2*-weighted brain MRI is analyzed 24 hours after injection to 
determine the tumor cell load in the brain (signals are only included within a pre-defined 3D 
brain mask (red) to avoid artifacts along the brain periphery). Only animals that have 
comparable tumor cell exposure are routed to further follow-up, e.g. comparing two 
treatments. (B) Imaging and morphological characteristics of metastatic spread and growth in 
mice resemble human melanoma brain metastasis; T1-weighted brain MRI, macroscopic 
image with corresponding 3D model, and H&E and HMB-45 (melanocytic marker) stainings. 
Adapted with permission from Sundstrøm et al.525. 
 
In Papers II-IV, we predominantly used the H1 cell line. This cell line was developed 
in our laboratory from a resected melanoma brain metastasis from a female patient521. 
The H1 cell line and its derivatives have been extensively characterized genetically 
and across multiple in vitro and in vivo assays (see Papers II-IV and other reports 
from our group520,521). The genetic profile of the H1 cell includes: BRAFV600E 
mutation, PTEN deletion, NRASwt, MITF amplification, CDKN2A/B deletion and 
LDHAwt. As described previously, this mutational profile is common in melanomas 
and in brain metastases. The cell line is highly tumorigenic in immunodeficient mice 
and rats when injected into the bloodstream (intracardiac or tail vein) or into the skin 
or brain, but it only forms brain metastases via the intracardiac route. Systemic 
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metastases consistently develop in the brain, adrenals, ovaries and bones. 
Interestingly, there is some shared ectodermal ancestry (brain, adrenal medulla and 
melanocytes), but circulatory explanations are probably more important determinants 
of this organ-selectivity. Akin to Cruz-Munoz et al.522, we have also done experiments 
with serial passaging in mouse brains to increase H1’s brain-tropic potential (not 
published). More brain metastases did arise with intracardiac injections of sequential 
generations, but protracted in vivo assays with subcutaneous injections of these cell 
lines did not result in systemic metastases, including to the brain. 
 
T2*-weighted MRI sequences are commonly applied to image SPIONs, which appear 
as local hypointensive spots526. Although SPION labeling has been reported to allow 
single-cell tracking527, we (and others) found that it is difficult to identify individual 
signal voids as single or multiple cells due to artifacts and partial volume effects528. 
To detect signals within the brain in a reproducible manner, we used a 3D brain mask 
(avoided artifacts along the brain periphery) and machine-learning tools (trained to 
identify signals). Automated signal detection was strongly correlated to manual signal 
registrations. The automated capacity substantially strengthens the applicability and 
throughput of the model, but it comes with a necessary trade-off between sensitivity 
and specificity. Therefore, our model does not provide an absolute number of cells in 
the brain, but a relative number that is proportional to the injected quantity. Most 
importantly, the model is predictive of brain metastasis formation. Taken together, 
quantitative analyses of SPION-labeled cells are model-specific and reliant on the 
SPIONs and cells that are used, as well as on imaging hardware and software. With 
the advent of stable MRI reporter genes and improved MRI technology, we can in the 
future envision the long-term tracking of cells and tumors through all stages of 
progression439. 
 
This model was streamlined towards comparative therapeutic in vivo assays; 
qualitative aspects of the early steps of brain metastasis are better studied using other 
methods, such as multiphoton laser scanning microscopy through cranial windows451, 
targeted MRI contrast agents444 or histopathological techniques453. 
 
This animal model was used in Papers III and IV. 
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6.3. Paper III 
The rewired metabolic network has emerged as an attractive venue for the 
development of novel anticancer drugs529. The metabolic enzyme LDHA plays a key 
role in the Warburg effect506,507 and is overexpressed in many cancers530-533. 
Preclinical studies have shown promising results of LDHA inhibition in several 
cancers533-542, but not in melanoma or brain metastasis. Metabolic networks are also 
complex and heterogeneous between and within various cancers543 and different organ 
environments can significantly influence tumor growth and metastasis, especially in 
the brain497-499. Furthermore, it remains unclear whether the Warburg effect is a 
contributor to or a consequence of cancer. With these perspectives, we explored the 
spatial, temporal and functional features of LDHA expression in melanoma brain 
metastasis across multiple in vitro assays, using our animal model (see Paper II) with 
brain MRI and PET imaging, and in a large patient cohort. We further assessed the 
contemporary genomic and proteomic landscapes of LDHA in different cancers, 
particularly melanomas, and associations to OS and brain metastasis-free survival in 
patients. 
 
We first investigated the temporal trends of LDHA protein expression during 
metastasis formation, and found a biphasic pattern over time and with tumor size: a 
strong expression in small tumors, reduced expression in enlarging tumors and 
regionally increased expression in the largest tumors (Fig. 17A). This prompted the 
hypothesis that LDHA was important during the early stages of metastasis formation, 
as well as later, when the tumors outgrow their blood supply. We thus explored 
LDHA protein expression in 80 operated human melanoma brain metastases and 
found it to be micromilieu-dependent and associated with larger tumors, but not with 
tumor number or survival. Hence, regionally increased LDHA protein expression in 
large tumors was seemingly without clinical consequence. Motivated by the 
contrasting preclinical findings with high LDHA expression in microscopic tumors, 
which are difficult to interrogate in patients, we developed an effective and stable 
LDHA knockdown cell line (short hairpin (sh)RNA interference) with significantly 
reduced glycolytic capacity. 
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Figure 17 LDHA expression displays a biphasic pattern over time, is hypoxia-dependent and 
does not influence survival. (A) LDHA protein expression in mouse melanoma brain 
metastases was high in small tumors and regionally distributed in large tumors. (B) LDHA 
protein expression in operated human melanoma brain metastases showed a spatial overlap of 
LDHA and HIF1α expression away from CD31-positive vessels. (C) LDHA knockdown by 
shRNA interference did not affect survival in mice. LDHA protein expression in 80 human 
melanoma brain metastases was not predictive of survival. LDHA gene expression in 82 
breast cancers did not predict brain metastasis-free survival (GSE2603 was the only dataset 
with this survival measure). H1_WT, naïve H1 cells; H1_LDHA_KD, H1 LDHA knockdown 
cells; H1_shCtr, H1 empty vector control; n.s., not significant. Adapted with permission from 
Sundstrøm et al.588. 
 
LDHA depletion did not affect cell proliferation or 3D tumorsphere growth in vitro, 
or the number and volume of brain metastases or survival in vivo. However, we 
confirmed that LDHA protein expression was strongly associated with hypoxia, both 
 86 
in vivo and in patients (Fig. 17B). Moderate degrees of LDHA staining were present 
in most melanoma samples featured in the Human Protein Atlas, but there were no 
samples from brain metastases. LDHA was genetically altered in only 5% of 375 
available TCGA samples and all of these were primary tumors or extracranial 
metastases. LDHA aberrations were generally infrequent in other cancer studies and 
melanoma series. Finally, LDHA expression levels did not predict OS in TCGA 
melanoma patients or brain metastasis-free survival in 82 breast cancer patients (only 
cancer series with this survival measure) (Fig. 17C). Together, these integrated 
analyses of independent genomic and proteomic data indicated that LDHA is not a 
driver of human melanoma brain metastasis or associated with survival. In summary, 
our findings show that LDHA expression varies with tumor size, but that tumor 
progression and survival seem to be functionally independent of LDHA expression. 
Thus, it is possible that the Warburg effect, observations of increased LDHA 
expression levels and increased serum levels of LDH, are more likely consequences 
of, rather than contributors to, melanoma brain metastasis. 
 
LDHA knockdown resulted in decreased glycolysis. Metabolic assays did not reveal 
any compensatory increase in LDHB or PDK1 expression with LDHA knockdown or 
hypoxia. We did however observe a slight increase of respiratory capacity in LDHA 
knockdown cells, but the mechanistic explanation for this was not explored further 
(e.g. induction of MITF and PGC1α). It is possible that the brain microenvironment 
abrogated the effect of LDHA knockdown by inducing a metabolic shift towards more 
oxidative respiration. Then again, we should probably have observed increased 
tumorigenicity in controls, but there were no differences in their in vivo phenotype. 
Other members of our group have also failed to demonstrate an effect of LDHA 
knockdown in an orthotopic glioma model (H. Espedal, personal communication). For 
these reasons, we did not pursue further investigations of migratory or invasive 
capabilities. 
 
Conclusively, our in vitro and in vivo results established that hypoxia is a key 
determinant of LDHA expression, but we were not able to detect any pro-metastatic 
capacity of LDHA in melanoma brain metastasis in vivo or in humans. The missing 
effect could be related to the limitations of single-targeting in cancer 
(intrinsic/adaptive compensation/resistance) or that LDHA is not a critical factor in 
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melanoma brain metastasis per se. Based on our results and currently available 
evidence, there seems to be more attractive targets or processes to pursue in brain-
metastatic cancer than LDHA. 
 
6.4. Paper IV 
In this study, we addressed several key hurdles to translational advances in brain 
metastasis research338 and described a potential new avenue of treatment for patients 
with melanoma brain metastases. We leveraged the merits of our brain metastasis 
model to define a brain metastasis gene signature and took advantage of the 
comprehensive Connectivity Map (cMap) pharmacogenomic database to identify 
compounds with the ability to invert this signature (Fig. 18A). Using this approach, 
we identified β-sitosterol, a natural compound and cholesterol analogue, which is well 
tolerated and used as a drug to treat hypercholesterolemia and benign prostatic 
hyperplasia. Moreover, β-sitosterol had shown anti-cancer potential in previous 
preclinical studies and been found to readily cross the BBB. We found that β-
sitosterol effectively reduced the growth of brain metastases and improved survival in 
established and preventive scenarios in tailored human xenograft models of melanoma 
and lung cancer brain metastasis (Fig. 18B-E). Of particular importance for metastatic 
melanoma, we found that β-sitosterol not only extensively suppressed the important 
MAPK pathway (Fig. 18F), but also inhibited mitochondrial respiration (Fig. 18G), a 
major facilitator of resistance to MAPK-targeted therapies. Furthermore, we provided 
evidence of the clinical relevance and prognostic utility of our findings at several 
independent levels. Together, this study strongly encourages further assessment of β-
sitosterol as an adjuvant to established MAPK-targeted therapies for patients at risk 
for, or that already have, melanoma brain metastases. 
 
We developed a 108-gene brain metastasis signature using a combined workflow of 
several independent comparative analyses of gene expression profiles in human 
melanoma xenograft brain metastases versus other organ metastases. Many of the 
signature genes were altered in TCGA melanoma patients, demonstrated significant 
individual prognostic utility, and were associated with a number of cancer-related 
signaling pathways. However, given the challenges of single-targeting in subgroups of 
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patients with metastatic disease, we opted for a multi-targeting approach to achieve 
more broad-spectrum efficacy and durability.  
 
 
Figure 18 β-sitosterol provides broad-spectrum suppression of melanoma brain metastasis. 
(A) Query results from the Connectivity Map (cMap) database using the 108-gene signature 
and the top 10 list of anti-brain metastasis compounds. In vivo assessments of β-sitosterol 
treatment: (B) subcutaneous macroscopic melanoma tumors, (C) established melanoma brain 
metastasis, (D) prevention of melanoma brain metastasis, and (E) prevention of lung cancer 
brain metastasis. β-sitosterol’s mechanisms of action: (F) broad suppression of the MAPK 
pathway through simultaneous targeting of its converging downstream regulators (ERK1/2, 
JNK1/2/3 and p38α) and corresponding transcription factors, and (G) high-resolution 
respirometry showing reduction of mitochondrial respiration through selective Complex I 
(CI) inhibition. Illustration by T. Sundstrøm. 
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Basically, we wanted to identify compounds that could counteract the entire brain 
metastasis signature and act in an anti-brain-metastatic fashion. We therefore turned 
to genomics-based drug repositioning and leveraged the cMap framework. We 
identified 1313 candidate compounds, carried out comprehensive in vitro screening of 
the top 10 candidates (all with cMap scores <-0.90, i.e. >90% of the expression 
profiles could potentially be reversed), and in vivo assessments of the four most potent 
compounds revealed β-sitosterol as a potential therapeutic agent. The therapeutic 
efficacy of β-sitosterol was confirmed using the H1 cell line in both established and 
preventive scenarios of brain metastasis, the H1 cell line in a macroscopic 
subcutaneous tumor model, and the aggressive PC14-PE6 lung cancer cell line in a 
preventive scenario of brain metastasis. 
 
The cMap database, first launched in 2006, is a powerful and freely available tool to 
find new uses for existing drugs544. cMap contains gene expression data from 
thousands of treatment versus control experiments independently performed on 
human cancer cell lines from breast, prostate, leukemia and melanomas. Drug 
repositioning has indeed been viewed as one of the most promising venues of 
translational medicine545, and a recent makeover and 1000-fold expansion of cMap 
will probably fast-track research and our understanding of drug repositioning. 
 
β-sitosterol: clinical applicability and anti-cancer potential 
The phytosterol β-sitosterol is structurally very similar to cholesterol, and is abundant 
in certain plants and foodstuffs, especially peanuts, tree nuts and avocados. β-
sitosterol competes with cholesterol for uptake via the intestinal Niemann-Pick C1 
Like 1 (NPC1L1) transporter546. The majority of β-sitosterol is re-secreted into the 
intestine via adenosine triphosphate (ATP) binding cassette proteins (ATP-binding 
cassette sub-family G members 5 and 8; ABCG5 and ABCG8)547, but some is 
transported by lipoproteins (mostly high-density lipoprotein (HDL)) and incorporated 
into cell membranes548,549. Less than 5% of β-sitosterol is absorbed, whereas 
approximately 50% of cholesterol is absorbed550. Intriguingly, β-sitosterol can cross 
the BBB551-553, whereas cholesterol cannot554,555. Additionally, β-sitosterol is to a 
higher degree incorporated into glial than neuronal cells, and brain accumulation in 
healthy mice has been found irreversible over a six-month period553. 
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RCTs in humans have found beneficial effects of β-sitosterol (and its ester sitostanol) 
on hypercholesterolemia556, benign prostatic hyperplasia557, androgenic alopecia558 
and as an adjuvant in the treatment of tuberculosis559 and anogenital warts560. 
Phytosterols are classified as “Generally Recognized As Safe” (GRAS) by the FDA, 
and the European Foods Safety Authority (EFSA) have concluded that a daily 
phytosterol and/or phytostanol intake of 1.5-2.4 grams can reduce blood cholesterol 
by 7-10.5% and sustain this effect for up to 85 weeks561. Notably, we used a daily 
dose of 5 mg/kg in our experimental studies of brain metastasis, which translates into 
375 mg for a person weighing 75 kg. To our knowledge, no clinical trials have 
examined the effect of β-sitosterol on cancer. However, a number of epidemiological 
studies have suggested that increased consumption of phytosterols can reduce the risk 
of breast562,563, lung564, stomach565 and colon cancer566. Furthermore, a wide range of 
studies have suggested several health benefits of nut consumption; recently, a dose-
dependent reduction in mortality from a number of diseases including heart disease 
and cancer was reported567. Interestingly, 100 g of roasted peanuts contain 61-114 mg 
of phytosterols (78-83% β-sitosterol)548. 
 
Experimental data have shown that β-sitosterol can reduce cell proliferation in 
prostate568, breast569, colon570, melanoma571 and lung572 cancer cell lines. Induced 
apoptosis has been observed in breast573, stomach574, colon575, myeloma576, 
hepatoma577, fibrosarcoma578 and prostate579 cancer cell lines. In an in vitro study with 
MDA-MB-231 breast cancer cells the authors found reduced proliferation, adhesion 
and invasion580. 
 
In vivo data have shown that β-sitosterol treatment can reduce the growth of breast 
cancer xenografts581, and that berry extracts with β-sitosterol can reduce 
tumorigenesis and progression in carcinogen-induced esophagus cancer582. Liposomal 
β-sitosterol treatment has been found to prevent metastatic lung colonization after tail 
vein injection of murine B16BL6 melanoma cells586. Oral treatment with phytosterols 
has been found to inhibit the growth of xenografted tumors and reduce lymph node 
and lung metastasis in a model using human PC-3 prostate cancer cells568. 
 
In summary, phytosterols have been shown to exhibit a number of different anticancer 
effects in vitro and in vivo, but the mechanisms of action remain somewhat elusive 
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(reviewed in583). They include effects on membrane structure and function, signal 
transduction pathways, apoptosis, cell cycle, antioxidant enzymes, free radical 
generation, immune function and cholesterol metabolism. Recently, it was suggested 
that phytochemicals (a long list of plant chemicals which includes phytosterols) might 
be applicable to melanoma therapy due to their low toxicity and ability to compromise 
several key pathways in melanomagenesis424. 
 
Putative mechanisms of action 
We found that β-sitosterol treatment massively reduced phosphorylation of multiple 
oncogenic kinases and transcription factors. Of particular importance for metastatic 
melanoma, we found extensive suppression of the MAPK pathway mediated by 
downregulation of ERK1/2, c-Jun N-terminal kinases (JNK1/2/3) and mitogen-
activated protein kinase 14 (p38α) as well as their corresponding transcription factors. 
Furthermore, in silico analyses associated major regulators of cell homeostasis to the 
therapeutic potential of β-sitosterol. From this, and previous work by us (see Paper 
III) and others496,497, we wondered if β-sitosterol could interfere with basic cellular 
functions such as energy metabolism. Intriguingly, we found β-sitosterol to 
substantially reduce mitochondrial respiration and respiratory capacity, and induce 
cellular ROS production and apoptosis. Further mechanistic studies revealed that β-
sitosterol exerted its effect by selective inhibition of respiratory CI. Taken together, 
our findings revealed a timely and potentially synergistic effect with particular 
relevance for patients with metastatic melanoma, as increased mitochondrial oxidative 
capacity has been shown to facilitate melanoma cell survival and growth, both as an 
intrinsic406 and acquired407 resistance mechanism to MAPK-targeted therapies. 
Furthermore, to survive and grow in the brain, cancer cells might be more reliant of 
functional mitochondria and mitochondrial respiration than glycolysis496,497,500. 
 
The abovementioned mechanisms are particularly relevant to melanoma and 
melanoma brain metastases, but other processes are also involved and might be 
important determinants of β-sitosterol efficacy. To name a few, we are currently 
studying membrane composition and protein-ligand interactions using atomic force 
microscopy, functional responses to fabricated microenvironments using 
combinatorial microarrays, blood levels of β-sitosterol, therapy in a canine melanoma 
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model, early metastasis/extravasation, migration assays, invasion assays and 
sequencing of treated and untreated cells and tumors. 
 
I would like to mention two other potential mechanisms of action that are not 
discussed in the paper. First, β-sitosterol has been found to inhibit the expression of 
endothelial VCAM-1584. Interestingly, a marked upregulation of VCAM-1 has been 
observed in the early stages of breast cancer brain metastasis in both mice and 
humans444. Second, β-sitosterol might activate LXR-mediated induction of 
APOE312,585. LXR agonism has been found to suppress melanoma tumor growth and 
metastasis, including brain-metastatic colonization, through transcriptional induction 
of tumoral and stromal APOE312. Moreover, APOE has been found upregulated in 
intermediate stages of melanoma brain metastases311 and β-sitosterol has also been 
shown to induce the expression of APOE in astrocytomas552. We investigated if β-
sitosterol treatment increased APOE levels and observed a modest increase in APOE 
levels over a course of three days, however a striking increase in particularly one 
APOE fragment. We are currently exploring these mechanisms in more detail. 
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7. CONCLUSIONS 
 
Paper I 
Animal models of human brain metastasis are useful, but do not reflect the complex 
biology of malignant disease in humans. Valuable insights have been attained, but 
there is a continued requirement of new and more representative animal models. 
Technical and biologic limitations of established animal models should be 
acknowledged and addressed.  
 
Paper II 
Automated quantification of nanoparticle-labeled melanoma cells in the mouse brain 
can improve the reproducibility and predictivity of an experimental human xenograft 
model of melanoma brain metastasis.  
 
Paper III 
LDHA expression in melanoma brain metastases was hypoxia-dependent, but did not 
seem to have a functional bearing on tumor progression or survival in vivo or in 
patients. 
 
Paper IV 
β-sitosterol inhibited melanoma brain metastasis and improved survival in vivo 
through suppression of the MAPK pathway and inhibition of mitochondrial CI. 
Genomics-based drug repositioning was feasible in a human xenograft model of 
melanoma brain metastasis. 
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8. FUTURE PROSPECTS 
 
Future prospects in melanoma and brain metastasis research are discussed throughout 
this thesis. Our group has built up considerable experience in experimental brain 
metastasis research and developed key relationships in Norway and abroad that 
provide great opportunities for the future. We are continuously seeking to improve 
our experimental set-ups and apply new methodologies. Our most recent work with β-
sitosterol is rapidly evolving; we are currently extending our preclinical understanding 
of its mechanism(s) of action and also exploring the possibilities of conducting a 
clinical trial. Besides β-sitosterol itself, our most interesting finding could be the 
apparent significance of mitochondrial respiration as opposed to glycolysis in 
melanoma brain metastasis. This relative insignificance of glycolysis for brain 
metastasis has previously been proposed for breast cancer brain metastasis. Whether 
therapeutic targeting of mitochondrial respiration has implications for brain metastasis 
in general and perhaps primary malignant brain tumors remains to be determined. 
Furthermore, the mechanistic links described in this thesis may reflect an even wider 
role in cancer, such as a synergistic coupling of mitochondrial biogenesis and 
respiration to migratory and invasive capabilities of cancer cells587. 
 
At present, we lack the necessary conceptual paradigms and computational strategies 
to make sense of all the information that is available, and to really understand what 
drives cancer in general and brain metastasis in particular337. Multidisciplinary efforts 
are needed to move beyond our fragmented understanding, and a stronger integration 
of preclinical and clinical knowledge is imperative for success. 
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